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ABSTRACT 
Half of Americans take a prescription drug, medical devices are in broad 
use, and population coverage for many vaccines is over 90%. Nearly all medical 
products carry risk of adverse events (AEs), sometimes severe. However, pre-
approval trials use small populations and exclude participants by specific criteria, 
making them insufficient to determine the risks of a product as used in the 
population. Existing post-marketing reporting systems are critical, but suffer 
from underreporting. Meanwhile, recent years have seen an explosion in 
adoption of Internet services and smartphones. MedWatcher is a new system that 
harnesses emerging technologies for pharmacovigilance in the general 
population. MedWatcher consists of two components, a text-processing module, 
MedWatcher Social, and a crowdsourcing module, MedWatcher Personal. With 
the natural language processing component, we acquire public data from the 
Internet, apply classification algorithms, and extract AE signals. With the 
VI 
crowdsourcing application, we provide software allowing consumers to submit 
AE reports directly. 
Our MedWatcher Social algorithm for identifying symptoms performs 
with 77% precision and 88% recall on a sample of Twitter posts. Our machine 
learning algorithm for identifying AE-related posts performs with 68% precision 
and 89% recall on a labeled Twitter corpus. For zolpidem tartrate, certolizumab 
pegol, and dimethyl fumarate, we compared AE profiles from Twitter with 
reports from the FDA spontaneous reporting system. We find some concordance 
(Spearman's rho= 0.85, 0.77, 0.82, respectively, for symptoms at MedDRA 
System Organ Class level). Where the sources differ, milder effects are 
overrepresented in Twitter. We also compared post-marketing profiles with trial 
results and found little concordance. 
MedWatcher Personal saw substantial user adoption, receiving 550 AE 
reports in a one-year period, including over 400 for one device, Essure. We 
categorized 400 Essure reports by symptom, compared them to 129 reports from 
the FDA spontaneous reporting system, and found high concordance (rho = 0.65) 
using MedDRA Preferred Term granularity. We also compared Essure Twitter 
posts with MedWatcher and FDA reports, and found rho= 0.25 and 0.31 
respectively. 
MedWatcher represents a novel pharmacoepidemiology surveillance 
informatics system; our analysis is the first to compare AEs across social media, 
direct reporting, FDA spontaneous reports, and pre-approval trials. 
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Introduction 
Half of Americans take a prescription drug [1]; many others make use of 
regulated medical devices both at home and in the clinical setting, and 
vaccination coverage for many vaccines is over go% [2]. Together, drugs, devices 
and vaccines have extended our lives and transformed our health. At the same 
time, nearly all medical products carry a risk of adverse events-harmful impacts 
caused by the treatment itself. Though in many cases these effects are mild or 
extremely rare, for some products in some contexts, adverse events can be severe. 
The process of clinical trials that precedes government approval is critical 
for evaluating both safety and efficacy of new medical products. However, clinical 
trials often exclude participants with multiple health conditions, who are taking 
other medications, or who don't fit specific clinical criteria [3, 4]. Further, due to 
inherently smaller sample sizes, clinical trials typically do not detect rare or 
extremely rare effects [5]. Meanwhile, once a product is approved, it is often 
prescribed to a much larger population of patients, many of whom don't fit the 
trial criteria. Further, approximately 20% of prescriptions are for "off label" 
usage, situations in which clinical trial outcomes have limited applicability [6, 7, 
8]. The result is that clinical trials are often insufficient to determine the true 
risks of a product as it is used in the population. In fact, over half of approved 
drugs have serious side effects not detected before approval [g]. Moreover, with 
increased use of opioids and certain new biologics, the incidence of serious 
adverse events in the US has increased in recent years, even after accounting for 
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the increase in prescriptions [10]. 
Agencies such as the Food and Drug Administration (FDA) and Centers for 
Disease Control and Prevention (CDC) are charged with protecting population 
health by carefully evaluating and managing the risks and benefits of each 
product on the market. Because of the clear need to monitor risks beyond clinical 
trials, the government has established a range of reporting mechanisms for 
industry, consumers, and clinicians, most notably FDA MedWatch and CDC 
Vaccine Adverse Event Reporting System (V AERS). For drugs, biologics, and 
devices FDA MedWatch [u, 12, 13], in particular, the 3500 Form [14], has long 
been the established channel for clinicians and pharmaceutical companies to 
report on post-marketing adverse events. For vaccines, VAERS [15, 16] is the 
preferred reporting mechanism. However, these systems are often cumbersome 
and oriented to expert clinicians (Figure 1). Even for clinicians, who are under 
professional obligation report, these forms represent another paperwork burden 
in an already overburdened workflow. Given these barriers for both patients and 
clinicians, the result is that adverse events often go unreported [17, 18]. A 2012 
study of hospitals by the Department of Health and Human Services Office of 
Inspector General found that 86% of reportable adverse events went unreported 
[19]. While not all of these adverse events were related to medical products (some 
resulted from improper procedure, highly complex cases, or other factors), 
clearly we face significant underreporting across our health care infrastructure. 
Of the reports that are collected through existing channels, So% of drug-related 
2 
reports [20], 35% of vaccine reports [21], and 98% of device reports [22] come 
from manufacturers, who are under legal obligation to report all events they are 
aware of. While manufacturer reporting is essential, without the direct 
engagement of patients and clinicians, we are missing a key piece of the picture. 
.... ,_. __ ........ , ...... 
.... ... -... ·-·---------~-· ----,.,... ___ .. _ ···----- .. _ ... 
·-·-~ .............. -
-. .... w ... -,_..... •' O•a--~~-~-· 0 
. ?;~~=-~-::-.:!.-;.;. ;-::;;:=::.-;~..;:..!. 
~;;:;_--;:::-::=:-..:_ ··=~~ .... ...... _,_ 
~~-t4:.;~- 1~f~~:. 
_.,_ .. ___ , ___ __ ., __ ,.,.._,_ , __ . 
.... _, ............ .. 
· ;.:z.~§f: :."".;.~~ 
--·- - -- I ::,~~'""'~~~J:::.c 
" - ·-- -·-·· - . __ .. , .,_ _ .. ___ .. __ 
···-·-·--·- ...... _. ____ .,.... ___ ~ 
~ -===- ~--_ _, 
·-::~'-'~-=-~~"'~ d 
·~-=-...:::-::~:::- I 
~~~=~ 
·· - ... ... - I ·~~~:," ---·.-.. -
-~-----·----· 
=~·--~=-=·==---· - = 
1:::::::.:::~=-··-- · =----
~~-:-. =:·=-~ ·=::;.":=::_"- ;-..= :..-:=.~ ....... -= 
::::;-.:;:·J-=::_:_ !==7=,.-~-,~---~~~~ 
,~~~:.!.';"~ '" -· j- -= . 
~~=:=~:=-===-=:__ 
'-·--·- _ ,,.,._ __ _...,._,. 
-~---=--·-
~····--- .. ~~-=----~-----~ -~-
==._:-::.::-..... -.";' :-.::.=:. .. _ 
~ = .:7----·--·-
3 
Figure 1. The FDA "consumer-friendly" voluntary MedWatcher reporting 
form (3500B). This simplified version was introduced in 2013. 
Another limitation of existing reporting systems such as FDA MedWatch 
and V AERS is that they are often slow to publish the data they collect. FDA 
Adverse Event Reporting System (F AERS), the mechanism by which the FDA 
publishes MedWatch reports, typically releases data on a quarterly basis, with a 
one-year delay. At the time of writing in February 2014, the data had not been 
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updated in over one year [23]. The data that are released come in large relational 
database files, with duplication and inconsistencies. The FDA's system for 
disseminating medical device reports, Manufacturer and User Facility Device 
Experience [24] (MAUDE), is better in that it is typically updated on a monthly 
basis, and searchable via a Web-based form, but is still challenging for non-
expert users. Although public health officials and regulators in government may 
have ready access to these data sets, the result of the delay is that manufacturers, 
clinicians, and the general public have limited opportunity to gain insights from 
these valuable reports. 
At the same time as we see both the impact of adverse events and major 
reporting gaps, we have an explosion in adoption of Internet services and mobile 
computing devices. In particular, adoption of social media tools and smartphones 
has surged: 160 million Americans are on Facebook [25], 140 million US-based 
accounts are on Twitter [26], and 46% of American adults own smartphones [27]. 
In the health domain specifically, as of fall 2012, 59% of US adults had looked 
online for health information in the past year, 35% had gone online specifically to 
determine a medical condition [28], while 52% of smartphone owners reported 
gathering health information through their phones [29]. Meanwhile, on the 
clinical side, fully 85% of US physicians own or use smartphones professionally 
[30]. 
In response to the challenges of adverse event reporting and the 
opportunities offered by emerging technologies, we present MedWatcher, a new 
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system for early detection and tracking of adverse events in the population at 
large. This new program builds on our earlier work in infectious disease outbreak 
tracking and in the broader field of digital disease detection. MedWatcher 
consists of two main components, a data-mining module, MedWatcher Social, 
and a crowdsourcing module, MedWatcher Personal. With the data-mining 
component, we acquire a broad range of data from the Internet, in the form of 
posts in public forums. We then apply document classification and information 
extraction algorithms to filter and classify the information and extract both 
individual and aggregate signals of adverse events. With the crowdsourcing 
application, we provide a mobile and Web-based application that allows users to 
both track safety information on their chosen products, and easily submit adverse 
event reports directly into the system. We then review and filter these reports and 
similarly look for both individual and aggregate signals of both known and 
previously unknown side effects. 
The job of public health officials, to keep beneficial, sometimes life-
changing, and sometimes life-saving therapies available while protecting us from 
their side effects, remains difficult. Given the noisy data available, primarily in 
the form of spontaneous MedWatch reports, when an apparent signal arises, 
there is often no clear answer on whether to change recommendations, labels, or 
pull a product from the market. With the work of this thesis, we can't hope to 
answer these thorny questions definitively. However, for the regulators, 
clinicians, and patients faced with these challenges, we offer a new arrow in the 
5 
quiver. We are seeing a situation of vast underreporting of adverse events, even 
as more and more people are equipped with easy-to-use, high-bandwidth 
reporting tools. With MedWatcher, we apply the power of new information 
technologies to provide a new window into understanding the adverse effects of 
medical products as they occur in the general population. 
In the work of this thesis, we seek to answer the following questions: first, 
can we engineer a system, MedWatcher Social, with sufficient automated 
classification performance to derive useful data from the noise of Internet media? 
Second, can we engineer a system, MedWatcher Personal, with sufficient 
consumer adoption to derive useful data by crowdsourcing direct reports? Third, 
if so, how do these new sources compare with available pre-marketing and post-
marketing surveillance sources? If the new sources match closely, then we have 
validation of the new signals, and the advantage of our new approach comes from 
speed and ease of access to the data. If they don't match, then two possibilities 
arise: one is that our new data sources are simply too noisy to be useful; the other 
is that our new sources offer important insights that are not available through 
existing channels. 
As shown in our results below, we find that we are indeed able to build 
effective systems for generating signals, and we find that they match to some 
degree with existing sources. In general, when we compare social media data with 
traditional MedWatch reports, we find legitimate adverse event signals in social 
media, but they tend to be weighted toward the more common, but less severe 
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side effects of the medication in question. In some cases we do see indications of 
more severe adverse events in social media as well, though at lower frequency. 
When we compare results from reports received through MedWatcher Personal, 
we find high concordance with MedWatch reports. In examining individual 
MedWatcher Personal reports, we likewise see more severe events than those 
found on social media. Although all sources, including the traditional surveillance 
methods, have limitations, our study indicates that these new sources represent 
useful complementary and potentially important tools for understanding 
medication safety, for both patients and the public health community. 
Background: Pharmacoepidemiology Foundations 
The tremendous benefits of modern medicine that we enjoy worldwide 
come inevitably with risks. The current era of medication safety and 
pharmacovigilance practice began with the thalidomide disaster of the 1960s. The 
drug was patented in 1954 by the Griinenthal Group, a German pharmaceutical 
company, and was initially made available as an over-the-counter general use 
sedative in 1957 [31]. It was introduced to the United Kingdom in 1958 [32]; by 
the early 1960s, it was prescribed as a treatment for nausea in pregnant women. 
In 1961, an Australian doctor noticed an increase in birth defects, particularly 
problems with development of limbs and extremities, among children born to 
mothers who had taken the drug. Meanwhile, in 1960 the US FDA refused to 
approve the drug, citing a lack of testing data from Griinenthal. With the 
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discovery of its teratogenic effect, the drug was withdrawn from the UK market in 
1961 and withdrawn from the market worldwide by 1962. Ultimately, over 10,000 
children were born with deformities linked to thalidomide exposure. The crisis 
led to increased pre-approval regulation for pharmaceutical products in both the 
US and Europe, and a number of civil suits against Griinenthal [33]. Though 
many other products have since been found to carry significant risks in post-
marketing and over so years have passed since regulators removed thalidomide 
from the market, its story remains in the public consciousness. The latest case 
was settled, and the company issued an official apology, as recently as 2012. 
Meanwhile, despite the disaster, a new form of thalidomide, pomalidomide 
(marketed as Pomalyst) was recently approved as a cancer drug, for treating 
multiple myeloma. With this drug, researchers were able to harness the same side 
effects of the medication that led to birth defects, namely its property of 
inhibiting angiogenesis, to inhibit tumor growth [34]. 
In many cases, the risk-benefit calculation, and the decision on whether to 
keep a product on the market or remove it, is more difficult. Zolpidem tartrate, an 
insomnia drug, was invented by Synthelabo and marketed initially in France in 
1988 and then as Am bien in the United States in 1992 by Sanofi-Aventis. It is 
widely used, with close to so million dispensed prescriptions in the US in 2007, 
the year the compound was authorized for generic production. In 2006, reports 
began surfacing of people sleepwalking, "sleep driving," eating, cooking, and 
performing other complex activities while on Ambien, and having no memory of 
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their actions [36]. Representative Patrick J. Kennedy of Rhode Island brought 
national attention to the issue when he crashed his car into a barrier at the 
Capitol Building in May 2006 and claimed amnesia, reportedly under the 
influence of Ambien [37]. Meanwhile, Sanofi-Aventis stated that "the safety 
profile of Ambien is well established," and that in trials, fewer than 1 in 1,000 
subjects experienced sleepwalking [38] (by comparison, the estimated national 
overall population prevalence of sleepwalking is between 1% and 15% [39]). Over 
500 patients filed a class action suit against Sanofi-Aventis in the US in March of 
2006 for failure to adequately warn them of the risks of the product. While no 
compensation was awarded as a result of the suit, the FDA compelled the 
company to modify the label information to include a warning for these effects 
[ 40]. To date, in FDA MedWatch, "Road Traffic Accident" is one of the most 
reported adverse events for zolpidem, with 620 reports [41, 42]. 
At the same time, questions around both efficacy and safety remain. A 
2007 study of newer sleep aids including Ambien found that as compared to 
placebo, on average, time to fall asleep was only 12.8 minutes less and sleep time 
was only 11.4 minutes more, though subjects reported believing they slept an 
additional32 minutes on average [43]. In 2013, a study by the Substance Abuse 
and Mental Health Administration (SAMHSA) found that emergency department 
visits related to zolpidem had more than tripled between 2005 and 2010 [44]. 
Also in 2013, the FDA required manufacturers to cut the recommended dose for 
women in half due to excessive morning drowsiness linked to the product [45]. 
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The zolpidem safety timeline illustrates the importance of continued 
pharmacovigilance across a broad range of products. Though the product has 
been marketed and widely used for over 20 years, we are still discovering new 
aspects of its safety profile and regulators are still making modifications to their 
recommendations to the public and clinicians as regards the drug. We monitor 
zolpidem with MedWatcher Social; some of the safety signals derived from our 
system for this product are presented below. 
Given the large number of products that carry risks of significant side 
effects, and the situation of massive under-reporting by both clinicians and 
patients, the time is apt for new approaches to pharmacovigilance. 
HealthMap: Foundations for MedWatcher 
Though with MedWatcher we focus on pharmacoepidemiology, our 
methodology has its roots in our infectious disease epidemiology work on 
HealthMap, an internationally recognized, award-winning disease tracking 
system launched in 2006 [46, 47]. The system relies on custom-designed data 
acquisition and natural language processing algorithms to gather and 
characterize real-time information from tens of thousands of Internet sources, in 
over ten languages. HealthMap then displays the information in an easily 
accessible, publicly available dashboard visualization (Figure 2). As part of our 
research work, in 2009 we launched a crowdsourcing component for HealthMap, 
collecting user contributions both on the Web and via mobile application (Figure 
10 
2), and deriving signals for infectious disease monitoring [48, 49]. HealthMap 
data provided one of the earliest indications ofthe novel H1N1 influenza virus 
outbreak in 2009 [50, 51] and, for this work, became an Official Selection by 
United States Library of Congress, Presidential Transition during a Time of 
Crisis. 
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Figure 2. The HealthMap main page (healthmap.org), offering an interactive 
map visualization of real-time disease outbreak alerts from Internet media. 
HealthMap is an internationally recognized leader in novel, Internet-
enabled public health surveillance. HealthMap was recognized in an interactive 
exhibit by the US Smithsonian Cooper-Hewitt, National Design Museum in New 
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York (2010), and has been featured on CNN, NBC Nightly News, in the New York 
Times, Wall Street Journal and other media outlets. The program has earned 
funding from a range of sources, including Google, the National Institutes of 
Health (NIH), the US Department of Health and Human Services (HHS), the US 
Centers for Disease Control and Prevention (CDC), the Department of Homeland 
Security (DHS), the US Agency for International Development (USAID), and the 
Bill and Melinda Gates Foundation. 
HealthMap Text Processing 
Like MedWatcher Social, HealthMap gathers health event data from 
publicly available online sources, primarily news media, by searching for disease 
names and other public health terms. The system filters the resulting articles first 
for relevance by means of a statistical whole-document classification system, 
placing each article into one of five categories, "Breaking News," a report of a 
currently ongoing outbreak, "Warning," a situation where no cases have been 
identified but an outbreak is likely to occur (such as a disaster situation), "Old 
News," where the outbreak in question is no longer ongoing, "Context," where the 
article is health related, but not referring to any specific outbreak, and "Not 
Disease Related." The algorithm performs with 93% recall and 92% specificity on 
the two-way classification task on English-language news media, as detailed in a 
Google Tech Talk presentation in 2008 [52]. This statistical approach, described 
in detail below, is re-applied to filter social media and Internet forum posts in 
12 
MedWatcher Social. 
The HealthMap system then performs a rule-based named-entity 
extraction step in order to identify disease and location, using a rapid, tree-based 
approach to match incoming text against a pre-defined dictionary of terms that 
map to disease and location concepts. The algorithm showed 89% accuracy for 
location and 94% accuracy for disease on a sample of English language news and 
public health reports [53]. This approach is also applied in MedWatcher Social 
for identifying product and symptom mentions in Internet posts, and is detailed 
below. 
HealthMap and StreetRx Crowdsourcing 
In early 2009, we added the first support for direct user contributions to 
HealthMap from the general public, in the form of functionality on the Web site 
allowing users to identify event reports by submitting uniform resource locators 
(URLs) for review. In fall 2009, we launched the HealthMap mobile app, 
Outbreaks Near Me for iPhone, the first large-scale disease outbreak surveillance 
crowdsourcing effort. The system consists of a client-side mobile application 
(now available for both iOS and Android operating systems), supported by a set 
of backend services integrating with the HealthMap Web site, allowing us to both 
push real-time information to mobile users, as well as receive, review, and triage 
reports (Figure 3). 
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Figure 3. The HealthMap Outbreaks Near Me mobile application, allowing ready access to 
location-specific disease outbreak iriformation and direct reporting capability for all users. 
Beyond infectious disease, we have also undertaken crowdsourcing efforts 
in the pharmacovigilance space. Particularly as opioid and stimulant use and 
abuse have climbed significantly in recent years [54, 55, 56, 57], the need for 
public health insight into abuse-related behaviors is critical. Addiction and 
overdose are both key adverse events for a range of widely used medical products 
and have massive public health impact. As part of our research in this area, we 
launched StreetRx (streetrx.com, Figure 4) in 2010 as a means for collecting 
information on black market prices for prescription drugs. The system serves 
approximately 1,000 visits per day and receives 1,000 price submissions per 
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month. The user-submitted information is consistent with street price 
information available from other sources, and consistent per unit of active 
ingredient across different doses (Figure 5). These crowdsourced data thus 
provide an important view into patterns of drug diversion, black market 
economics, and the illicit prescription drug user community [58]. 
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Figure 5. Price per milligram cross-comparison of StreetRx price reports with 
law enforcement reports and the Silk Road online marketplace [58]. 
HealthMap Surveillance Key Results 
Although with HealthMap we have focused on the infectious disease 
realm, we have shown the effectiveness of capturing Internet media for public 
health practice. By tapping online sources in real-time, and applying automation 
to achieve scalability, HealthMap has consistently been able to identify emerging 
disease threats ahead of traditional sources. In 2007, using comprehensive 
official World Health Organization (WHO) data, we analyzed avian influenza 
infection events and found that HealthMap collected corresponding informal 
reports on average 2.3 days (95% confidence interval: 0.7- 3.9) prior to official 
reports (Figure 6). HealthMap also collected some of the first signals of the 2009 
H1N1 influenza pandemic, and was able to track the spread of H1N1 around the 
world in the early days of its emergence [50, 51]. As part of a retrospective study 
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of H1N 1 dynamics, we were also able to identify patterns of reporting lag by 
country, finding somewhat greater lags between informal and formal reports in 
lower-income countries [59]. We also undertook a historical analysis of 400 key 
outbreak events, across a range of pathogens, as identified by the WHO over a 
period of a decade, establishing reporting timelines for each event. In particular, 
this study illustrated that over the 10-year period, both time to outbreak 
detection and time from detection to official announcement decreased [ 6o] 
(Figure 7). 
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In parallel, our crowdsourcing efforts around HealthMap have yielded 
important signals as well. The Outbreaks Near Me app saw substantial adoption 
during the second wave of H1N1 infection starting in September 2009. In a 2010 
study of user-submitted HealthMap data, we found that an indicator based on 
volume of submissions for influenza events in the US mirrored official reporting 
data (Pearson's correlation: 0.74, Figure 8), and further found several individual 
situations where user reports contained valuable early information either not 
found in existing HealthMap sources, or only confirmed later [48, 49]. Most 
recently, we have turned to social media sources to derive signals on infectious 
disease outbreaks, finding early indicators of H7N9 influenza activity in China 
based on information from Sina Weibo, the Chinese microblogging service 
similar to Twitter [61]. Beyond tracking outbreaks themselves, we have also 
harnessed HealthMap technology to tap news media and blogs for understanding 
attitudes and beliefs towards vaccines in the general public [62]. 
18 
VI 
~ 
·c;:; 
·:; a 
"' VI Cl! 
c:: 
=7 
~ 
-;:;; 
~ 6 
QJ 
:::> 
<;::: 
c:: 
·-. 0 
g', 
"' ~ ' I 
5:i I 
l: I 
QJ I 
c. ' I 
4J I 
c:: I 
::; I 
u ' I 
Cl I 
U I 
Date: 1 September 2009 to 15 January 2010 
\ 
\ 
\ 
\ 
\ 
\ .... , __ , \ 
' \ \ 
\ 
\ 
' ', 
' 
' 
' 
' \ \ I 
\ I 
' I .......... 
, ... 
I \ 
I \ 
, \ 
.... \ / \ 
I \ 
I \ 
I \ 
I \ 
---coc Ill % ---us iPhone reports per new user 
Figure 8. Adjusted volume of H1N1 crowdsourced reports from HealthMap Outbreaks Near Me 
users as compared to weighted influenza-like-illness visit data .from the CDC, .from September 5, 
2009 to January 30, 2010 [48, 49]. 
Although pharmacovigilance is a new application of these approaches to 
public health surveillance, with new challenges and pitfalls, with HealthMap we 
have demonstrated the power of harnessing new media for public health 
surveillance. Meanwhile, since the early days of our HealthMap work, the volume 
of publicly available real-time information, adoption of social media services, and 
adoption of smartphones has skyrocketed. 
MedWatcher Social 
At the same time that we see significant underreporting of adverse events 
through official channels, new Internet services have given voice to many 
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millions of people who now can share their personal experiences in public 
forums, including their experiences with medical products. Approximately 25% of 
Facebook profiles and go% of Twitter feeds are fully public [ 63, 64 ], and a broad 
range of health-focused discussion forums support public discussions. Some 
initial research work on extracting adverse event reports from public posts has 
already been conducted [ 65, 66, 67]; we build on this work by expanding the 
scope of analysis to a broad range of products and data sources, and creating a 
scalable, real-time system. 
For the purposes of MedWatcher, at the most basic level, an adverse event 
report consists of an identified medical product, a specific patient, and a 
physiological or cognitive symptom that either the patient or caregiver believes is 
due to the product. Beyond these basic elements, the FDA traditionally requires a 
valid report to include both an identifiable patient and an identifiable person 
reporting the event [68]. However, though we expect to see both of these in many 
MedWatcher reports, we don't require that the patient or reporter be identifiable, 
as our primary objective is to identify product-symptom associations. The 
distinction here is important: throughout the thesis, we use the term "adverse 
event report," or "adverse event post" in the sense of our looser definition as fits 
the nature of the data, as opposed to the strict definition used by the FDA and in 
the field of traditional pharmacovigilance practice. 
Beyond the product and the symptom, a complete adverse event report can 
encompass a raft of potentially relevant additional data, such as the condition for 
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which the product is prescribed, the dose and frequency of use of the product, 
other medications, other medical conditions, the date of the event, the patient's 
clinical details before, during, and following the event, the age and gender of the 
patient, the manufacturer's lot number of the product, the product itself (or a 
sample), its packaging, or more. Though we also expect to see a range of 
reporting details, in most cases, especially when the report comes from a 
consumer, we will have only a subset of information to work from. 
System Architecture 
The basic structure of the MedWatcher Social software is illustrated in 
Figure g. The acquisition engine collects data via the use of source-specific 
application programming interfaces (APis) or custom-developed screen scraping 
programs, and stores it into a replicated document database, MongoDB [6g]. We 
then build the curation tools, algorithms, and data exports and visualization 
around the database. 
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Figure 9- MedWatcher Social system architecture: the acquisition engine loads posts into the 
database; we then build tools and data outputs around the database. 
The process begins with data Acquisition; we then perform manual 
supervised labeling and develop our Product and Symptom taxonomies. With 
these in hand, we apply three separate text processing algorithms, Information 
Extraction, Document Classification, and De-duplication, with a cycle of learning, 
testing, and development feedback throughout (Figure 10). 
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Figure 10. The cycle of data acquisition, classification, training, and evaluation in MedWatcher 
Social. 
Acquisition 
If we hope to identify meaningful indicators by aggregating posts in any 
way, consistent data acquisition is the critical first step in deriving signals from 
Internet sources. If we have lapses in data collection or shifts in collection 
methodology, we necessarily introduce noise into any aggregate data. Secondly, 
our acquisition strategy determines our overall corpus of data from which to 
derive signals. Given the volume represented by these sources, with likely over 
6oo million posts per day [70, 71], and the technological, budgetary, and 
algorithmic limitations of the thesis project, we cannot capture every piece of 
content. Since an adverse event report must contain mention of a product, we use 
our list of product names as search terms, and limit the data set by including only 
posts where the product name is mentioned. The drawback of this approach is 
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that we will miss mentions where the product name is misspelled, referenced via 
slang or abbreviation, or referenced in a separate post as part of a conversation. 
Conversely, for some products, we also see excessive noise when the product is a 
topic of popular culture (e.g., Viagra), or where the product name has another 
commonly used meaning (e.g., Actos, Ella, Intermezzo, Yaz), making it difficult to 
monitor safety information for these products, at least under the current 
approach. 
For collecting Twitter posts, we make use of the Twitter "streaming" API 
[72], which allows us to supply a list of search terms, and returns a continual, 
real-time flow of matching tweets in a structured, machine-readable format. We 
then extract key data fields from these records and store them in the MongoDB 
database. In addition to selecting effective search terms, one of the key challenges 
of Twitter data acquisition is maintaining the continuous operation of the feed 24 
hours per day over multiple years. Due to network connectivity failures, request 
timeouts, operating system process management issues, Twitter service 
downtime, or other failures, the streaming connection may drop at any time. To 
overcome this challenge, we implemented an automated fail-safe system to detect 
when data collection has stopped, and accordingly restart the streaming process. 
With this system, we lose no more than one minute of real-time data when a 
typical failure occurs; if a rare server-level failure occurs we may lose up to fifteen 
minutes of data. Though these occasional data drops introduce some noise into 
the system, overall they are within tolerable levels given the plentiful volume of 
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data and the time resolution of the signals we seek. 
For harvesting Facebook data, we make use of the Graph Search API [ 73]. 
This service similarly allows us to input search terms and receive a set of 
matching records. Since it is not a streaming service, our software polls the 
service regularly for matching posts over a fixed time frame. We use overlapping 
time windows and match incoming content with existing records to ensure we 
have a comprehensive data flow. We query Face book for public posts matching 
product names; due to the properties of the API, the result is not only posts that 
contain the specified keywords, but also any post where a user comment on the 
post contained a search term. In cases where the original post does not contain 
any keyword (i.e., only a comment mentioned the term), we drop the post in 
order to reduce noise. Likely in some of these cases we eliminate relevant 
content, but we found it a necessary step in order to maintain reasonable volume. 
Supervised Labeling 
Once we've collected the data corpus, one of the key challenges of 
MedWatcher Social is determining consistent standards among our analysts for 
labeling posts. At the time of writing, we have a team of trained analysts who 
review and label content for the system, including the thesis author (who has 
personally labeled close to 10o,ooo posts at the time of writing). A detailed 
description of the curation protocol is provided in the supplementary materials. 
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For the purpose of the current study, we consider a post to be an adverse event 
report if it contains a reference to a medical product and some expression that 
the product is either ineffective, or a symptom is due to the product. Further, the 
event must be a specific experience; that is, results of studies of a population 
(e.g., "25% of subjects experienced nausea"), or general statements ("Metformin 
may cause nausea") are not considered adverse event reports. Examples of 
adverse event reports, as well as posts not meeting the criteria, and how they are 
classified by product and symptom, are illustrated in Figure u; the curation 
dashboard is shown in Figure 12. The dashboard allows curators to search by 
category ("tag"), product, and free text, as well as access the original content in 
context on its site of origin (e.g., Twitter or Facebook). The dashboard also allows 
users to search machine-tagged posts by indicator score, to allow for "active 
learning," as detailed further below. As expected, ambiguous situations often 
occur, especially where the post author's language is unclear as to what event 
occurred, or whether it is attributed to any medical product. In these cases, the 
team will occasionally review content together and attempt to form consensus. 
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I just took two Klonopin and a Xanax, 
so if I don't ever wake up ... l'll miss 
some of you. 
Figure 11. Sample Twitter posts illustrating how the system identifies key terms, and some of the 
challenges of classification. The post mentioning Klonopin and Xanax is ambiguous (could be 
classified as "incorrect dose']; the post mentioning Ambien is clearly a joke; the other two are 
clear adverse events, where specific symptoms are attributed to specific products. 
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., Validate All Shown 
0 AP.926 + Weed couldn 't get me h1gh lol l 've taken morphine since I was 6th 
gradery'all don't know about my kinda high 
0 AP.938 + Leg super pamful this moming, so have taken a couple of paracetamol 
& codeine tablets, now feel ing fuzzy al l over, but no leg pain, hurrah 
0 AP.997 + If only I'd known my vaccin t1on would make my arm swell up, I 
probably would have asked for it in the arm I don 't have to sleep on ... 
#doh! 
0 AP.955 + @IC i honestly th ink i died .... ambien makes me feel the 
same when i fight the sleep and start getting wavy. lol 
O . Ne 
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04:09:36 
2014 
4 Mar 
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Figure 12. The MedWatcher Social curation dashboard allows analysts to search, review, and 
label individual posts. 
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We performed a preliminary curator agreement study in which two 
curators independently labeled 3,319 Twitter posts for AE vs non-AE, and found 
high concordance as reported below. However, to date, we have focused primarily 
on accumulating a large corpus of labeled data, rather than overlapping efforts. 
In the curation process, we assign each post to one of five categories: (1) 
Junk, such as a spam post (2) Other Mention, a legitimate mention of the 
product, but no adverse event reported (3) Possible AE, a post with possible AE 
properties but needing further review (4) Adverse Event, a post fully meeting the 
criteria (5) Clinical AE, an adverse event post where the event included some 
interaction with a health care provider (generally more severe events). 
Besides assigning a label to the document, curators also assign products 
and symptoms, and collect patterns to add to the product and symptom 
dictionaries as described below. 
Product and Symptom Taxonomies 
The basic elements of a post that constitutes an adverse event report for 
our purpose are the product, and the symptom that appears to be linked to the 
product. We thus maintain a taxonomy for each of these elements. 
With medical products, for each product, we capture its name, its generic 
name, corresponding search terms (typically the product name or a substring of 
the name; misspellings and slang terms for a few products), and a set of 
synonyms for identifying product mentions in our data corpus. These synonyms 
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form the product "dictionary" as used in the information extraction step as 
detailed below. Though they are linked, we include both brand names and generic 
names as separate product entries in the taxonomy, allowing us to track them 
separately. For medical devices, we take the device functional name (e.g., 
"defibrillator") as the product generic; for vaccines, in most <;ases we use the 
disease name along with "vaccine," "vaccination," or "shot," such as "Hep B shot," 
as a generic. Lastly, for drugs only at this point, we capture both the common 
drug indications (e.g., Ambien: insomnia) and desired effects (e.g., Ambien: 
sleepiness/tiredness), and link those to the symptom taxonomy. 
For our symptom taxonomy, we maintain the symptom name (in its 
simplest colloquial form where possible, otherwise using clinical language), and 
then a set of synonyms for each symptom, again allowing us to form a dictionary 
for automated symptom extraction from text. In the case of symptoms, the 
challenge of identifying mentions is much more difficult than for products, as the 
colloquial terms, abbreviations, and metaphors that people use to describe their 
symptoms vary much more. While for products we have an average of 1. 7 
synonyms per product, for symptoms, we have 15 on average. One key feature of 
the symptom taxonomy is the entry we term the "masking entity." The masking 
entity is not a true symptom category, but exists purely to capture patterns for 
preventing false positive matches. For example, in our taxonomy, "high" is a 
synonym for the symptom entity "altered state of consciousness." Under the 
masking entity, we put "high dose," "high price," "high cost," etc., so that when 
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those terms appear, though they contain "high," they do not trigger a match for 
altered state of consciousness. 
Lastly, we link each colloquial symptom category to a MedDRA term. With 
over 70,000 lower-level terms organized into five levels of hierarchy, the Medical 
Dictionary for Regulatory Activities (MedDRA) [74] is a comprehensive 
taxonomy of symptoms, diagnoses, procedures, and other medical concepts that 
serves as the international standard for pharmacoepidemiology practice. Linking 
to MedDRA allows us to take advantage of its hierarchy of concepts. At its top 
level, MedDRA groups symptoms by System Organ Class (SOC), such as Skin, 
Nervous System, Psychiatric, etc, followed by High Level Group Terms (HLGT), 
then High Level Terms (HLT), then Preferred Terms (PT), then Lower-Level 
Terms (LLT). 
Irifonnation Extraction Algorithm 
For MedWatcher Social, we apply the HealthMap tree-based dictionary 
matching algorithm to identify both product and symptom mentions. It consists 
of three components. First, we load the dictionary from its easily editable 
spreadsheet form into the tree structure in memory. At this step, the two separate 
product and symptom dictionaries are superimposed into a single tree, allowing 
us to make only a single pass over the input for both product and symptom 
matches. Second, for the extraction step, the tokenizer strips punctuation and 
splits the input into a series of tokens, typically corresponding to words. Finally, 
30 
we process the tokens one at a time, matching each against the tree and 
traversing the tree as matches occur. If we reach a leaf in the tree, then a positive 
match is established and we return the identifier for the appropriate concept 
(product or symptom). The matching process can identify any number of 
concepts in a given block of input text. 
The algorithm exhibits linear performance on the length of the input text, 
and can easily accommodate large dictionaries of hundreds of thousands of 
terms, limited only by memory. An illustrative sample tree structure of the 
dictionary as loaded into memory is shown in Figure 13. At the time of writing, 
the system recognizes 1,230 drug, device, vaccine, biologic, and cosmetic 
products through a dictionary of over 2,300 terms. It tracks 257 symptom 
categories, using a dictionary of over 4,8oo terms. As we continually label posts, 
we continually grow and refine these dictionaries as new concepts and synonyms 
appear. 
12 
13 13 
As we process the input token by token, we 
Each node is a hashtable. 
Each key maps an input token 
either to an 10 or another node. 
traverse the tree accordingly. 14 
Figure 13. The HealthMap tree structure for matching dictionary terms against an input text, 
here applied to symptom matching for MedWatcher Social. 
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In addition to identifying product and symptom concepts for a given 
document, we also provide a visualization of specifically which terms in the origin 
text gave rise to which concept matches, as illustrated in Figure 14. We achieve 
this term highlighting by first capturing the coordinates of the matching tokens in 
the tokenized form of the text; we then perform an alignment step to match each 
token with its original position in the raw input text. We can thus embed the 
match information as visual annotations in the original text, giving users direct 
feedback on how the algorithm arrived at its results, and helping curators rapidly 
refine the term dictionaries. 
RT @" - Essure: Al l my joints ht..r! today #essureproblems had a hard time walking today ... #essure is crippling thousands!! 
RT @ ~ - : Dear Dr.'s Check your malpractice coverage #Bayer throws Dr. under the Bus death caused by #Essure · 
Xanax vallums klonopins, !eating. I may never come down again 
I would rather die by cervical cancer than die by a reaction to a vaccme 
Figure 14. Semantic highlighting based on the information extraction and alignment process. 
Device names are highlighted in blue, drugs in red, vaccines in yellow, and symptoms in green. 
The limitations of this dictionary approach are several: first, the dictionary 
must be populated and maintained by curators, who must use judgment when 
choosing the synonym patterns. Specifically, as we don't yet have a framework for 
assessing sensitivity and specificity for a given individual pattern, we lack a 
quantitative methodology for determining whether to include a pattern or not. 
Secondly, the approach is fully rule-based, and so unable to take advantage of 
statistical models of context, in terms of syntax or semantics, to determine 
whether a given pattern applies. 
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Document Classification Algorithm 
While the information extraction algorithm is rule-based, we employ a 
statistical approach for automated document classification, i.e. categorizing each 
post as whole. For simplicity, at this phase, we group our five classifications into 
two categories, non-AE and AE, namely categories 1 and 2 (Junk, Other Mention) 
for the former, and 3, 4, and 5 (Adverse Event, Possible AE, Clinical AE) for the 
latter. As AE versus non-AE is the most important distinction for our purposes, 
we still maintain usefulness of the classifier while simplifying the already 
challenging task it must perform. 
Feature Extraction 
The first step in the process, and indeed in almost any machine learning 
classification approach, is feature extraction. That is, we decompose each input 
document into a set of discrete elements ("features") that are likely to reoccur 
across distinct documents. As we process our training data, we tally the number 
of times each feature occurred in an AE post (a "positive") and the number of 
times it occurred in a non-AE (negative) post, to form the "model" for the 
classifier. Ideal features are those that appear frequently in posts falling in one 
category but not the other. 
We take a two-part approach to feature extraction in MedWatcher Social. 
First, we process the text itself. In this phase, we convert URLs into a single 
common token (on the assumption that the presence or absence of a URL is a 
better indicator of post status than the precise text of the URL itself), then 
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convert all text to lower case and tokenize the post body into unigrams, digrams, 
and trigrams. That is, we take all single words, two-word, and three word 
subsequences as separate features. At this phase we also employ a set of common 
"stop words," such as "the," "and," "it," and remove any of these n-grams that 
consist only of stop words. 
The second component of feature extraction is to apply the information 
extraction algorithm as described above and identify product and symptom 
mentions as features for the post. As a secondary step, we also compute all the 
product-symptom combinations from these mentions, and note those as features 
as well. If the post contains no symptom mention or no product mention, we 
record that absence as a distinct feature in itself. Lastly, for drugs, we make use of 
the indication and desired effect information from the drug taxonomy, and 
remove all previously identified symptom features where the symptom is either 
an indication or a desired effect of one of the mentioned products. After this step, 
if there are no symptom mentions remaining, we again apply the absence of 
symptom as a distinct feature. 
With the corpora of training data at the time of this writing at 
approximately 140,000 tweets and 30,000 Face book posts, the number of 
distinct features resulting from decomposition is 2 million for Twitter, and 5 
million for Facebook. We initially used Kyoto Tycoon [75] as a dedicated key-
value store for storage and retrieval of the model, but found it lacking in features 
and scalability for this application. We successfully switched to using Mongo DB 
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to store the training feature sets and have found it to exhibit high performance 
and scalability for our purposes. We further implemented a MapReduce [76] 
pipeline for the extraction step (map) and the tallying step (reduce). Though we 
have not yet deployed it on a parallel processing infrastructure, we do take 
advantage of a built-in multi-threaded sort function, and as we increase the 
number of documents, we will be able to easily scale feature extraction by parallel 
processing. 
One effect of the large feature set resulting from natural language 
processing of large document corpora is that it makes matrix-based machine 
learning tools such as Weka [77] impractical. While Weka does support sparse 
feature matrices (our feature matrices are extremely sparse in this case), it still 
requires us to index each feature, leading to impractically large index values and 
limiting flexibility. However, since Weka has recently introduced new features 
making it more adaptable to large data sets, one possible avenue of future work 
includes experimenting with Weka. 
Note that though the current feature extraction algorithm is adapted 
primarily for Twitter posts, we use the same algorithm for Facebook posts as well. 
Also to be noted is that by using our information extraction algorithm to generate 
features in the second step, we make the performance of the document 
classification algorithm dependent at least in part on the performance of the 
information extraction step. With these caveats, and feature extraction in hand, 
we then turn to our statistical machine learning computation. 
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Fisher-Robinson classifier 
We adapted the HealthMap statistical document classification algorithm 
to the problem of predicting whether a given Internet post refers to an adverse 
event or not. The algorithm is based on the classifier concepts detailed in "A 
Statistical Approach to the Spam Problem" [78]. A more in-depth description of 
the algorithm is given in Appendix A. In summary, we take our target document, 
that is, the previously unseen document we wish to label as an AE or non-AE, and 
apply the same feature extraction algorithm. Then for each feature, we compute 
an adjusted probability value based on the database of counts of how frequently 
the feature appeared in an AE post and how frequently it appeared in a non-AE 
post. We then combine the probabilities using the inverse chi-squared (X2 ) 
function and calculate an overall indicator score. A score close to o indicates the 
post is unlikely to be an adverse event; a score close to 1 indicates it is highly 
likely to be an AE post. As a final step, in an ad hoc measure found to boost 
performance, where applicable, we deduct a "no symptom penalty'' from the 
indicator score. If the post contains no identifiable symptom from our 
information extraction step, it is less likely to contain a true adverse event report, 
so we deduct a pre-determined value ( 0.2 at the time of writing, determined 
empirically) from the indicator score. Figure 15 gives a summarized view of the 
steps and equations we use in the Fisher-Robinson classifier. 
For each token "w": 
• b(w) = (AF.s containing w) I (total AF.s) 
• g(w) = (non-AF.s containing w) I (total non-AES) 
b(w) 
p(w) = b(w) + g(w) 
(s *X)+ (n*p(w)) 
f(w)= s+n 
H = c-1 (-2ln nf(w),2n) S = c-1 (-Zln n 1- f(w), Zn) 
w 
l+H-S 
1=--2--
w 
Figure 15. Summary of computation for Fisher-Robinson document classification algorithm. s 
and x are hyperparameters of the model; G-1 is the inverse X 2 function. 
Nai"ve Bayes Classifer 
A detailed comparison of the mathematical underpinnings of Fisher-
Robinson and Na1ve Bayes classifiers is given in Appendix A. For comparison, as 
an alternative to the Fisher-Robinson classifier implemented for HealthMap, we 
also implemented a Na1ve Bayes classifier, using the same feature extraction 
method, but calculating the indicator score using the Na1ve Bayes approach. 
Specifically, we computed an indicator by taking the sum of the adjusted log 
probabilities for each term in the target document. In this case, the indicator 
score ranged from approximately -900 to 300, with the large positive value 
indicating high likelihood of an AE report. We similarly applied a "no symptom 
penalty" to this indicator score; the value we used was 10 given the indicator 
range properties. Figure 16 illustrates the basic calculations of the N a1ve Bayes 
approach. 
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(1) P(D lA) = n P(wt lA) 
i 
P(A n D) 
(3) P(AID) = P(D) 
P(A n D) 
(2) P(DIA) = P(A) 
P(A)n (4) P(AID) = P(D) P(w1 lA) 
i 
P(A)n (5) P( -AID)= P(D) P(wt 1-A) 
i 
P(A ID) P(A) ~ P(wtiA) 
ln P(-AID) = ln P(-A) + ~ ln P(wd -A) 
l 
Figure 16. Computation used in the Nai"ve Bayes classifier. A represents the "positive" (adverse 
event post) outcome; D represents the given document; w; represents the ith token in the 
document. 
Active Learning Approach 
Once we had established substantive training sets for both Twitter and 
Face book (tens of thousands oflabeled posts each), we then began using the 
classifier to automatically label the raw stream of incoming data. Given the large 
volume of data, and especially the large volume of negative posts (Junk and Other 
Mention), it is impractical to manually confirm or correct every machine-labeled 
post in these prospective data sets. In particular, given also that a sizable portion 
of the data exhibits regularly recurring patterns, and is easily classified correctly 
by the classifier, it's not an efficient use of analyst time to examine these posts. 
We therefore introduced a feature into the dashboard to allow curators to search 
the machine-labeled posts by giving a range of the indicator score (shown in the 
upper left of the curation dashboard, Figure 12 above). By reviewing only posts 
that fall in the middle of the indicator range, the analyst can then reduce his or 
her workload while at the same time providing labeled examples of the posts that 
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the classifier deemed most ambiguous. This approach, where we use elements of 
the classifier output to select training examples, is termed "active learning." [79] 
In addition to the training and classification steps, it introduces a feedback loop 
between the classifier and the analyst team providing the gold standard labels. 
Since we've only recently introduced this practice, we have not yet evaluated its 
effectiveness relative to our previous ad hoc labeling approach. 
De-Duplication 
The final component to the suite of text processing steps is the de-
duplication algorithm. With both the Twitter and Facebook data, we see frequent 
cases where an original post is subsequently reposted ("retweeted," in the case of 
Twitter). The result is a large volume of posts with nearly exactly the same 
content as the original post. Duplication poses problems at a few levels. First, it 
potentially distorts the aggregate signal we hope to derive from the data. Second, 
it imposes unnecessary burden on the analysts if they must label the same 
content repeatedly. Lastly, it potentially distorts machine learning performance 
metrics, first by overemphasizing the importance of features found in duplicate 
posts, and second, if duplicates are distributed across the training and testing 
sets, it falsely boosts performance. 
To combat these problems, we implemented a basic algorithm that takes a 
set of posts in chronological order, creates a sliding window of posts 
(approximately one day), and compares the text of each subsequent post to all 
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posts in the window. At this point, we use a built-in string comparison algorithm 
in PHP [So] to compute a similarity percentage for any two posts. We then set a 
threshold (currently at So% similarity) and assign a given post as a duplicate of 
the earlier post if the similarity percentage is above the threshold. 
Once the duplicates are identified, we hide them from the curation 
dashboard, exclude them from the document classification training sets, and 
exclude them from data outputs and aggregate analysis. Due to project 
constraints and priorities, we have not yet performed any rigorous analysis of the 
performance of this de-duplication algorithm. 
MedWatcher Social: Classifier Evaluation Methods 
Before we present results of the text processing performance, we first 
detail the methods undertaken for framing and calculating these results. 
Information Extraction Evaluation 
For the project thus far, we have been in a ramp-up phase where our main 
focus has been on building out the taxonomies, and the corresponding 
dictionaries, thus making the extractor a moving target for rigorous analysis. For 
the product classifier, because our acquisition strategy relies on product names as 
search terms, and because product names are typically distinctive an 
unambiguous, the product classifier has high accuracy, requiring little 
intervention. 
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However, we have undertaken two separate performance studies of the 
symptom extraction component. First, in fall 2013, as part preparation of our 
manuscript submitted to Drug Safety, we took a random sample of manually 
labeled AE Twitter posts and assessed the symptom classifier by reviewing each 
post and its assigned symptoms by hand. In this review, we tallied the correct 
symptoms (those due to the product) and the total extracted symptoms, and 
computed true positives, false positives, and false negatives accordingly. 
Secondly, in December 2013, we introduced the capability for curators to 
manually assign both product and symptom categories to a post. With this new 
gold standard data, we are now able to compare the output of the extractor with 
the assigned categories using an automated script. One caveat to keep in mind is 
that again because we are continually building out the dictionaries, these 
examples will be "tainted" with specific patterns that curators have collected from 
the posts we are testing against. Nevertheless, the evaluation yields at least a 
rough gauge of performance and insight into the viability of the approach. 
Document Classification Evaluation by Cross Validation 
Meanwhile, we have focused considerable effort on evaluating (and 
improving) the statistical document classification algorithm. Specifically, we 
created a randomized cross-validation framework whereby we can take either the 
entire labeled corpus, or a specific subset of interest, divide it into N pieces, train 
the classifier using N-1 of the pieces, and then test its classification properties on 
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the Nth piece. The framework allows us to set a threshold value for the indicator, 
above which the classifier predicts a positive, allowing us to compute precision, 
recall, and specificity metrics. The system also outputs the indicator value, the 
true label, and the post content, to allow for receiver operating characteristic 
(ROC) and precision-recall curve analysis as well as manual inspection of 
incorrectly predicted examples. Though we use randomization and cross 
validation to prevent over-fitting, we still run some risk, first by creating our 
product and symptom dictionaries from the full corpus, and second simply by 
potentially tuning the parameters to the overall properties of the corpus, which is 
not randomly sampled from the raw data and therefore may not be 
representative. 
For our key performance evaluation measures, we use precision (what 
epidemiologists refer to as "positive predictive value"), recall ("sensitivity" for 
epidemiologists), and F-measure. F-measure is computed as 
2 * precision * recall 
F - measure = ---.-.-----
preclszon + recall 
Specificity is another common performance measure, as are ROC curves, which 
plot recall against 1- specificity for the range of possible cutoff values. However, 
because our data are noisy, with actual rates of true positives under s% (see 
below), specificity is generally high, simply because the classifier is able to 
correctly label a large number of true negatives such as spam, etc. As a result, 
specificity is a less useful performance measure. 
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MedWatcher Social: Classifier Evaluation Results 
Classifier performance: information extraction 
We assessed the precision and recall of the symptom dictionary matching 
algorithm at two separate points in the project. First, we performed manual 
classification of a random sample of 437 Twitter posts that analysts had labeled 
as adverse event reports, considered as a gold standard. A single post can contain 
multiple symptom mentions; a symptom match was considered a true positive 
only if the symptom was considered an adverse event of one of the mentioned 
products. On this initial sample, we found precision was 72% (410 I 573), and 
recall was 86% (410 I 475). One key aspect to note about this analysis is that to be 
as conservative as possible, we have not excluded the symptoms that are listed as 
indications or desired effects for many of the products in the product taxonomy. 
Had we set the algorithm to exclude these symptom matches, the rate of false 
positives would likely have been lower and therefore the precision would be 
greater. 
For a second analysis, we took a larger set of 6,413 Tweets that we have not 
only labeled as adverse event posts, but also assigned structured product-
symptom combinations to capture the specific events described. Futher, in this 
second analysis, we incorporated the information from the product taxonomy by 
removing matches for indications and desired effects. We find precision 0.77, 
recall 0.88 and F-score 0.82 as shown in Table 1. 
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Incorporating Precision: 0.77 
indications 
and desired 
effects from 
product 
taxonomy 
True positives: 
4478 
Recall: 0.88 
False positives: 
1322 
F-score: 0.82 
False negatives: 
613 
Table 1. Performance summary for the information extraction algorithm. 
One caveat for these results is that we have applied a strict standard of 
exact category matching in order to merit a true positive. For example, pain, 
injection site pain, and muscle pain are all separate categories; if the extraction 
yields "pain" but the correct category was "injection site pain" the instance is 
recorded as a false positive (pain) and a false negative (missing injection site 
pain), though the categories are obviously related. The same applies for category 
groups such as: "overdose" and "incorrect dose"; "nausea," "vomiting," and 
"malaise"; "migraine" and "headache." A further limitation of the evaluation is 
that it doesn't separate true mentions of the symptom that are not attributed to 
the product ("I felt sick until I took Advil") from simple erroneous pattern 
matches ("I go to Belmont High" ["high" matched as "altered state of 
consciousness"]). Future work includes building up relationships between 
categories in the taxonomy and improving both the extraction algorithm and its 
evaluation accordingly. 
Though information extraction can clearly be improved, the overall 
performance indicates that we can for the most part expect aggregate signals 
based on automated symptom extraction to be at least in line with what we would 
likely derive from manual, gold standard symptom labeling. 
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Classifier performance: preliminary inter-rater agreement study 
As noted, we have thus far focused on building up the labeled corpus as 
rapidly as possible rather than overlapping efforts. However, we did perform a 
preliminary inter-annotator agreement study on 3,319 tweets. The study found a 
large degree of agreement, yielding a Cohen's Kappa score of 0.97, with the 
confusion matrix as shown in Figure 17. Tweets, due to their brief nature and 
often confusing syntax, represent challenges for consistent labeling, as do the 
more lengthy Face book posts that may encapsulate a long history of experiences 
with drugs and medical conditions. As an analysis team, we are continually 
discussing and refining our labeling methodology to produce both a useful 
training set for our classifier and meaningful signals in the data and reporting 
outputs. Future work will include more formalized system infrastructure for 
capturing and evaluating inter-annotator agreement statistics. 
r2b 
r la 1 2 Total 
1 3,166 33 3,199 
2 19 181 128 
Total 3,185 134 3,319 
Figure 17. Confusion matrix for inter-annotator agreement study. "r1a" and "r2b" are the two 
analysts; 1 indicates a non-AE post; 2 indicates anAE post. Cohen's Kappa is ((52 I 3319) - o.so) 
I (1- o.so) = 0.97. 
Classifier performance: document classification 
Eight-fold cross validation of all labeled, de-duplicated Twitter posts (total 
N=137,000), with an indicator cutoff value of 0.7 (range: -0.2 to 1.0), yields 0.68 
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precision, 0.89 recall, resulting in an F-measure of 0.77. Area under the ROC 
curve is 0.96, belying the actually weaker performance of the classifier as noted 
above. The more instructive precision-recall curve for the Twitter classifier, with 
area under the curve of 0.81, is shown in Figure 18. (ROC and precision-recall 
curves generated using the ROCR library for R. [86]) 
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Figure 18. Precision-recall curve for the Fisher-Robinson document classifier on Twitter posts. 
The color value indicates the value of the cutoff along the range from -0.2 to 1.0. Area under the 
curve is 0.81. 
When we run the same cross validation without including the product and 
symptom information extraction, the performance drops to 0.6 precision, o.g 
recall. As noted above, for document classification, we are somewhat dependent 
on the performance of the information extraction step, though it appears to 
account for only 10 percentage points of precision under current conditions. 
For Facebook, the classifier is less developed than for Twitter, with fewer 
labeled training examples and fewer targeted symptom dictionary terms. Eight-
fold cross validation for Facebook posts (total N=37,000) yields precision 0-46, 
recall o.6g, with area under the precision-recall curve being 0.57 (Figure 19). 
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Figure 19. Precision-recall curve for the Fisher-Robinson document classifier, on Facebook 
posts. Area under the curve is 0-57· 
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For comparison, we also implemented a Na!ve Bayes classifier, using the 
same feature extraction methods. With the indicator value (sum of log 
probabilities) ranging from -goo to 300, we chose a cutoff value of 10, which 
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yielded precision: 0.72, recall: 0.75, and F-measure: 0.74 on the Twitter corpus. A 
precision-recall curve for the Naive Bayes classifier, with area under the curve of 
0.78, is shown in Figure 20. 
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Figure 20. Precision-recall curve for the Nai"ve Bayes classifier, on Twitter posts. Area under the 
curve is 0.78. 
While the document classifier still needs improvement, the current 
performance indicates that we have the potential to scale the system beyond what 
even a dedicated team of analysts could achieve through manual labeling, and 
derive signals from the corpora without being overwhelmed by the noise. 
MedWatcher Social: Signal Analysis Methods 
Product Selection 
For our analysis of the actual adverse event signals in the data, because of 
the broad scope of the project, we must unfortunately make at least somewhat 
arbitrary decisions on where to focus our efforts. For our initial analysis, we 
selected products representing a mix of therapeutic areas, time on market, and 
known or perceived risks. 
As an example of an established product with a known safety profile, we 
chose zolpidem, the insomnia drug that has been available since 1992. We use a 
product such as zolpidem so that we can compare our results with a rich set of 
pre-existing safety information, to both confirm the validity of our approach, as 
well as characterize how our novel data sources differ in nature from traditional 
sources. 
We then chose to focus our efforts on products that have relatively recently 
been approved by the FDA, where we can potentially provide timely safety 
insights where post-marketing information is currently limited. We therefore 
take a subset of the products that have been approved since 2007, and then 
further limit the set to those with the top volume of mentions in our corpus. As a 
demonstration of analysis for this type of product, we analyze certolizumab pegol 
(brand name: Cimzia). 
We also look specifically at products recently introduced that are 
designated by the FDA as "new molecular entities" (NME), meaning that they are 
chemical substances to which humans have not previously been exposed on a 
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large scale (as opposed to newly approved drugs that are reformulations of 
previously approved and tested compounds). All other factors being equal, 
because of their novelty, these products have the greatest potential for important, 
previously unknown adverse events to occur in post-marketing. Our full selection 
of NME products is shown in Table 2. Thus far only one of these, dimethyl 
fumarate (Tecfidera) is sufficiently mentioned in our social media corpus to allow 
for even preliminary analysis. Among medical devices, we focused on the Essure 
permanent contraceptive device, due to our ability to match results from social 
media with crowdsourcing via MedWatcher Personal. As part of the results 
presented below on MedWatcher Personal, we present an analysis of both social 
media findings (from MedWatcher Social) for this device as well as direct reports 
received through the MedWatcher Personal app. 
Product 
afatinib 
alogliptin 
apixaban 
dolutegravir 
ado-trastuzumab, 
emtansine 
golimumab 
mipomersen 
canagliflozin 
dabrafenib 
dimethyl fumarate 
Brand Name 
Gilotrif 
Nesina 
Eliquis 
Tivicay 
Kadcyla 
Simponi 
Kynamro 
Invokana 
Tafinlar 
Tecfidera 
Disease Condition 
cancer 
diabetes 
atrial fibrillation 
HIV/AIDS 
cancer 
rheumatoid arthritis 
cholesterol 
diabetes 
cancer 
relapsing multiple 
sclerosis 
ospemifene Osphena pain during intercourse 
oxybutynin transdermal Ditropan, Gelnique, Oxytrol incontinence 
pomalidomide Pomalyst cancer 
radium Ra 223 Xofigo cancer 
trametinib Mekinist cancer 
Table 2. Full list of new molecular entities (NMEs) as designated by the FDA. 
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Though for the purposes of this thesis, we must choose a limited subset of 
products for deeper analysis, we are currently tracking over 6oo products. (Our 
product taxonomy encompasses over 1200 products but not all of them have 
currently active search terms.) While many of them yield little data because they 
are not widely used, one of the key contributions of the thesis is that we now have 
the framework in place to track and analyze a broad range of products, both 
prospectively and retrospectively. 
As we examine aggregate signals for a given product, we use the overall 
number of product mentions as a background comparison. Though it's difficult to 
determine an appropriate denominator in this type of analysis, given the inherent 
noisiness of the data, the total mention volume at least gives one piece of context 
for interpreting absolute numbers of adverse event posts. Naturally, if a product 
is widely used, it may see greater numbers of adverse event reports, though it is 
not necessarily more dangerous or more prone to side effects. 
Known Product Label Information 
Having chosen our products of interest, we then compare the adverse 
event profiles generated from social media with the AEs identified in clinical 
trials and reported on the product label. Drug label information is unfortunately 
not available in a structured format that would yield easy access to the adverse 
event profile for a given product, in a quantitative form. As a result, we have 
manually collected and tabulated label AE data simply by locating labels in 
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portable document format (PDF) from manufacturer Web sites and reading 
through them. We also manually compiled data from the NIH DailyMed, RxList 
and MedScape Web sites, which organize label data for a range of drugs and 
make it publicly available [81, 82, 83]. 
FDA Spontaneous Adverse Event Reporting Data 
While the clinical trial outcomes represented in labels capture the pre-
approval picture of adverse events, we must also compare our signals with the 
existing post-marketing surveillance data. The FDA Adverse Event Reporting 
System (F AERS) and CDC's Vaccine Adverse Event Reporting System (V AERS) 
have been in place for decades and form the national standard for post-market 
pharmacovigilance [11, 15, 23]. Though these data are available in somewhat 
structured form, unfortunately, they are not well organized either: they are 
delayed and often contain duplicate information and inconsistent product 
identifiers. Fortunately, we have been able to make use of data sets compiled by 
AdverseEvents, Inc. [84]. 
Matching Data Sets for Comparison 
The clinical trial and F AERS data are both coded using MedDRA 
terminology to capture the symptom and diagnosis concepts. We thus match our 
social media data similarly by using the MedDRA mappings that are incorporated 
into the symptom taxonomy as described above. However, in many cases, 
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matching symptoms across systems is challenging. The challenge is in part 
because the MedDRA terms used in FAERS are often more fine-grained or 
clinically specific than what we can capture from spontaneous layperson posts in 
social media. Secondly, in some cases the MedDRA term used in FAERS is 
difficult to map to reported text. For example, in F AERS we might see the 
MedDRA term "Abnormal Sleep-related Event," a vague category. 
As a result of these issues, we take the following steps as part of the 
comparison procedure: first, for some cases, we map multiple FAERS MedDRA 
terms to a single MedWatcher Social term. For example: Somnambulism, Sleep-
related Eating Disorder, Sleep Walking, and Abnormal Sleep-related Event are all 
mapped to the MedWatcher Social category "sleepwalking" (MedDRA: 
Somnambulism). Second, to further reduce noise, we roll together multiple 
related MedWatcher Social categories into a single category. For example, 
"anger," "irritability," and "emotional instability" are all mapped to "emotional 
instability" (linked to MedDRA term "Emotional disorder"). This last step is not 
strictly necessary and future work will include analysis without this step. The full 
set of mappings for each product analysis is included in Appendix B. 
We also make use of the MedDRA hierarchy to group related symptoms 
together, to reduce noise and improve overlap. We compare at the Preferred 
Term level, then roll all counts into the corresponding High Level Terms (HLTs) 
for comparison, then also roll counts into the broadest MedDRA grouping, 
System Organ Class (SOC). We would ideally use only the more granular 
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categories, for a more precise comparison, but the challenges of interpreting free 
text and mapping it consistently to structured categories persist across all these 
data sources, both traditional and novel. 
Once we have a consistent set of symptom terms, we can then rank them 
by frequency of report for the given product, within each source. To compare 
sources, we employ Spearman's Rank Correlation [85] as a measure of how 
similar the rankings are. The p-value associated with the Spearman's correlation 
indicates the probability that there is actually no association between the two 
rankings. We also present a ranked bar chart visualization allowing for easy 
visual comparison of relative magnitude. 
For the moment, given the current performance of the automated 
information extraction and document classification, and the challenges of 
symptom matching, we use only MedWatcher Social records that have been 
either manually labeled, or automatically labeled and then confirmed by an 
analyst. As noted above, with comparison across sources, we seek to answer the 
question of whether the new sources confirm existing sources, or offer new 
information. 
Lastly, because of the novel nature of the data sets, we present some 
specific anecdotal examples of note, to illustrate for the reader the character of 
the data. Though the selection and analysis are not rigorous, they serve to 
demonstrate some of the challenges of correctly categorizing these posts, as well 
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as the potential for insights to be gained as we move forward with developing the 
system. 
MedWatcher Social: Signal Analysis Results 
Characterizing Twitter and Facebook 
Since we began collecting Twitter data in late October 2012, we have 
collected over 19 million tweets; we have collected over 4 million Facebook posts 
since the start of data collection in March 2013. It is difficult to estimate the 
percentage of posts out of the raw volume that constitute AE reports (positives). 
Because of the large volume of posts, we are unable to simple label every post in a 
given time frame and then calculate the percentage accordingly. Even random 
sampling is problematic, because there is still the challenge of accounting for day-
of-the-week and hour-of-the-day effects. As an example, a random sample of 10% 
of Twitter posts over a one-week period in January yielded 30,000 posts. Even at 
1% sampling, or 3,000 posts, the labeling job is onerous. 
However, we estimate the prevalence of AE posts in Twitter, with the 
current set of search terms, to be between 2% and 4%. This estimate is based on 
the recent data and our evaluation of the classifier performance. Specifically, we 
base our estimate on analysis of the past three months of data, December 2013 to 
February 2014. For December and January, the percentage of AE posts is 2-4% 
(38,058 I 1,589,993) and (38,425 I 1,378,817) 2.8% respectively, while the 
percentage for February is 5.1%. However, given first that the precision of the 
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classifier is in the 60-70% range while the recall is 80-90%, there are many more 
false positives than false negatives. If we take 67% as precision and 90% as recall, 
we can adjust the number of positives by first subtracting 33% and then adding 
back 10%, so subtracting 23%, or roughly one quarter. We thus have around 2% 
for December and January and 4% for February thus far. 
Facebook yield appears to be slightly higher, at approximately 4%, though 
since we are still ramping up our work with Face book, the calculation is even 
more inexact. Based on January and February 2012, we see 5.6% for both for the 
raw numbers (11278 I 200802 and 16665 I 298213). With precision at so% and 
recall at 70%, the net adjustment is reduction by 20%, yielding around 4.5%. 
In general, because Facebook offers a forum capability, a number of 
patient forums have developed on Face book. These forums offer patients who are 
using medical products an opportunity to share their experiences with others in a 
longer format, as compared to Twitter. We thus find that while Twitter offers a 
larger overall volume of posts, Facebook has the potential for more valuable 
signals, especially for medications used in less common disease conditions, 
because of these patient forums. 
As noted below, in the Twitter data we find that as compared to MedWatch 
data, the complaints appear to be enriched for milder adverse events. 
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Comparison 1: zolpidem tartrate (Ambien) 
We first compare MedWatcher Social data collected from Twitter with the 
adverse event reports collected and published through the F AERS system. At the 
Preferred Term (PT) level, we find limited concordance, with a Spearman's Rank 
correlation (p) of 0.18, p-value 0.14, 95% confidence interval [-0.15- 0-47] [87]. 
At the HLT level, the correlation reaches significance, but is still weak at p = 0.53. 
Finally, with aggregation to SOC, we have p = 0.85. Correlation and uncertainty 
values across the three levels are shown in Table 3; comparisons by magnitude 
are shown in Figures 21-23. 
Zolridem 
Symptom Spearmanp p-value 
Aggregation 
Level 
Preferred 0.18 0 .14 
Term 
High Level 0 .53 0.001 
Term 
System Organ o.85 0.002 
Class 
Approximate mentions in Twitter corpus: 230,000 
Total manually confirmed AE tweets: 1,700 
Total FAERS counts: 11,180 
95% Number 
confidence of ranks 
interval (N) 
[ -0.15- 0 -47] 38 
[0.22- 0-74] 32 
[0.62 - 0 .94] 17 
Table 3: Concordance measures between MedWatcher Social Twitter data and FDA FAERS 
reports for zolpidem tartrate, at varying symptom granularity. 
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Figure 21. Comparison by magnitude ofF AERS spontaneous reports (left) with Twitter AE posts 
(right) for top reported symptoms (MedDRA Preferred Terms) associated with zolpidem. 
Spearman's Rank Gorreiatlon: 0.53, p = 0.001 
FAERS 1992·2012 MedWatcher Social (2013-2014) 
Figure 22. Top reported zolpidem symptoms in FAERS (left) and Twitter (right) at the MedDRA 
High Level Term level. 
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Spearman's Rank Correlation: 0.85, p = 0.002 
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Figure 23. Zolpidem symptom comparison by SOC. 
Of note in the comparison at the Preferred Term level, Road Traffic 
Accident is the fourth most commonly reported adverse event for zolpidem in 
F AERS, while we don't even have it as an available outcome category in 
MedWatcher Social. However, we do see some signal for driving-related events in 
Twitter, if we simply search zolpidem adverse event posts for "drove" or 
"driving." A sampling of these results is shown in Figure 24, including one actual 
accident, "drove into a mustang on ambien once." Meanwhile, Abnormal Dreams 
is one of the top reported outcomes in Twitter, and it is completely missing from 
the F AERS reports. The most likely explanation for this gap is that Abnormal 
Dreams is one of the milder effects, not rising to the level of importance for either 
a patient or clinician to file a report with the government, yet worthy of sharing 
with friends on an online social network. 
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That one t ime I was h1g off am bien and I had no idea I drove to meet 
shannonm:J @cuzimda_illest 
Better than that time I took ambien before I drove home and oor't remember 
getting home, but woke up hours later a block f rom my house. -_-
My cousin drove to Popeyes and ate a whole meal while on ambien. She didn't 
l"'lOOr a thing. 
Drove 30 miles on ambien and n t remem none of it. 
"@- ---:::· 'ii: @,... £ ::--..:::::::::::;, drove into a mustang on ambien once"O[]O 
Benadryl makes me 1'1 r. Ambien freaked me out. I drove 
r mber it 
Figure 24. Sampling of zolpidem AE tweets reporting driving under its influence, including one 
road traffic accident (highlighted in red). 
For Facebook data on Ambien, we don't yet have enough data (N = 66 
validated AE posts, 1236 automatically tagged but unvalidated AE posts) for 
meaningful comparison. As with Twitter, some top symptoms include Drug 
ineffective, Abnormal dreams, Altered state of consciousness, and Amnesia. 
For the adverse events reported from clinical trials as reported on the 
product label, we see limited to no concordance with any of the post-marketing 
data (Table 4). The few symptoms with any differential as compared to the 
placebo group are not enough to make a quantitative comparison worthwhile. 
Notably, of the top symptoms from either F AERS or Twitter, only Amnesia, 
reportedly affecting 0.5% of participants, only in foreign trials, appeared in 
clinical trials [88]. Given the safety profile of zolpidem as it is now known, the 
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limited signals that appear in the pre-approval data underscore the importance of 
maintaining and bolstering post-marketing surveillance systems. 
Short-term trial 
Symptom Percent of Percent of 
treatment placebo control 
subjects, subjects, 
N=6Ss N=473 
Drowsiness 2 0 
Longer-term trial (28-35 nights) 
Symptom Percent of Percent of 
treatment placebo subjects, 
subjects, N = 152 N= 161 
Dry mouth 3 1 
Allergy 4 1 
Influenza-like 2 0 
symptoms 
Palpitation 2 0 
Drowsiness 8 5 
Lethargy 3 1 
Drugged feeling 3 0 
Sinusitis 4 2 
Pharyngitis 3 1 
Table 4· Zolpzdem symptoms wzth greater than 2 percentage poznt hzgher prevalence in treatment versus 
placebo, as reported from clinical trials. Though full symptom comparisons are not listed for all trials, the 
label information reports that 1,701 people received the drug in domestic pre-approval trials and 1,959 
received it in foreign trials, of which 4% discontinued due to an adverse event. 
To illustrate the types of posts we see from Twitter, we present a few 
examples in Figure 25, selected by browsing AE posts with particular focus on 
more concerning events, such as amnesia and driving under the influence. While 
most of the posts reporting abnormal dream patterns don't give any cause for 
concern of morbidity, occasionally we see cases where it is a troubling side effect 
and could potentially be cause for the person to stop taking the medication, as in 
the last tweet in Figure 25. 
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Ov .!. Follow 
O v Follow 
Only amnesia I had was from Arnbien, 
the sleep med. I'd get up, get 
dressed, drive to a store, go 
shopping, and go home, not 
remember a thing 
Did I mention my ass hurts?!? What 
the hell did AMBIEN make me do?? 
So I was not a good person on ambien and it messed me up bad. 
But there were times where it worked and I sk miss sleep ugh 
O v ·.!.. Follow 
.. feel ing horrible ~ Follow Ambien stage 1- flashbacks of every 
I have had a freaking migraine all damn day! My Dr gave me 10 mg vivid dream I've ever had on a loop. 
am bien for my insomnia and I think that's the reason for my Slowly becoming hard to tell from 
migraine and the fact that I've been ti red all day! So I th ink I'm 
gonna have to find a way to cut that itty bitty pi ll in half!! reality. 
Figure 25. Sample AE tweets and Face book posts for zolpidem. The tweet in the lower right 
indicates a case where the abnormal dreams impact the user's experience beyond a minor 
annoyance. 
Overall, from this cross comparison, we can draw a few conclusions of 
note. First, just based on clinical trials, zolpidem appears to be generally quite 
safe. However, the low volume ofFAERS reports (only a few thousand total, even 
as some tens of millions people in the US are using it) is difficult to interpret as 
an overall gauge of safety, given the general phenomenon of underreporting for 
this channel. At the same time, the small numbers of patients included in clinical 
trials is itself notable. If a given adverse event were to affect just 1 in 1000 people, 
in a trial of 700 subjects, such as the one presented on the label as the only 
quantitative source of adverse event information, we would see the event only 
so% of the time (1- o.ggg7°0 = o.s), assuming an unbiased random sample. 
Meanwhile, with just 10 million users in post-marketing, on average, 10,000 
people would experience the event. Secondly, though we see some concordance 
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between Twitter and FAERS, especially at the broader MedDRA categories, we 
see that in the Twitter data the more common, milder effects of the drug, such as 
ineffectiveness, altered state of consciousness, abnormal dreams, etc., have 
greater representation. However, we do see a few symptoms of note in Twitter 
including amnesia and hallucination, and including a small number of reports of 
driving under the influence. 
Comparison 2: certolizumab pegol (Cimzia) 
Certolizumab pegol (Cimzia) is a monocolonal antibody to tumor necrosis 
factor alpha (TNF-a), used in the treatment of Crohn's disease, rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis. Approved 2008, the 
biologic differs greatly from zolpidem tartrate as far as its safety profile. First, it is 
an injected product, intended to affect the immune system, as opposed to a pill 
intended to affect the brain. It is much less widely used than zolpidem, and treats 
more severe and debilitating conditions, with fewer treatment options. As a 
result, patients tolerate more severe side effects, and regulators rightfully accept 
greater risks, in order to achieve the intended effect of the medication. As before, 
cross-matched Spearman's correlations are shown in Table 5, visual comparisons 
in Figures 26- 28. 
Certolizumab pegol 
Symptom Spearman p 
Aggregation 
Level 
Preferred 0.18 
Term 
p-value 
0.13 
95% 
confidence 
interval 
[-0.14- 0.47] 
Number 
of ranks 
(N) 
40 
High Level 0.50 0.0022 [0.17 - 0.73] 30 
Term 
System 0.77 0.00024 [0.44- 0.92] 16 
Organ Class 
Approximate mentions in Twitter corpus: 3,322 
Total manually confirmed AE tweets : 91 
Total FAERS counts: 13,714 
Tables: Concordance measures between MedWatcher Social Twitter data and FDA FAERS 
reports for certolizumab pegol, at varying symptom granularity. 
certollzumab pegol (Cimzla) 
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Spearman's Rank Correlation: 0.18, p = 0.13 
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Figure 26. Comparison ofF AERS spontaneous reports (left) with Twitter AE posts (right) for 
top reported symptoms (MedDRA Preferred Terms) associated with certolizumab. 
Spearman's Rank Correlation: 0.5, p = 0.0022 
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Figure 27. Top reported certolizumab symptoms in FAERS (left) and Twitter (right) at the 
MedDRA High Level Term level. 
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Figure 28. Certolizumab symptom comparison by SOC. 
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Although we have many fewer reports from Twitter, interestingly, the 
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concordance levels for certolizumab pegol appear to be roughly similar to those 
generated for zolpidem. We likewise see the milder effects, such as Drug 
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Ineffective, Fatigue, and Injection Site Pain, represented more in the Twitter 
data. It's further likely that some of the complaints categorized as Pain in Twitter 
are in fact Injection Site Pain, but either they are not fully correctly coded, or the 
post author is not specific about the location of the pain. 
In clinical trials, top symptoms for certolizumab include upper respiratory 
infections or inflammation of some form, including nasopharyngitis (common 
cold), pharyngitis (sore throat), rash, and urinary tract infections. Notably, 
Hypertension is included as a key symptom in the clinical trial data, but does not 
appear in the post-market reports. We also see warnings on rare but severe 
events, including cancer and tuberculosis infection, though no quantitative 
indication of risk for these events. Though the full breakdown of symptoms 
across the entire trial treatment population is not available, label material reports 
that approximately 1,500 Crohn's disease patients and over 2,000 rheumatoid 
arthritis patients received the drug. At the same time, the post-marketing 
treatment population is multiple orders of magnitude smaller than for zolpidem, 
with the manufacturer reporting 41,000 patients treated as of 2012 [90]. 
The selected example posts, with varying severity as shown below in 
Figure 29, illustrate how some of these experiences are expressed. Perhaps most 
notably, one of the Facebook posts includes a photograph of the patient's hand, 
showing a rash she believes to be due to the medication, thus bolstering the 
plausibility of the report. 
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Ov _ Follow 
My left arm where I get my cimzia 
shot is ssoo sore!! 
rheumatoidarthritis rheum 
arthritisfriendly arthritis RA 
Sausage Toes and Scales. Living Life with 
~ Psoriatic Anhrltis 
24 hours after dose 2 o f Cimzia and he re come the s ide effects . I 
guess dose 1 wasn 't enough to t ip off my immune response hel l. 
Headache Is throbbing, bli stering and sores on my tongue and 
gums, nausea bad enough that if I could vom it I would, low grade 
feve r, fat igue, and arthrit is flare has kicked in. At least my 
infl ammation seems to be limited to my arthrit ic jo ints and not 
systemic. Yeah??!? 
Ov Follow 
rr i was itchy all 
over in humira and cimzia 
shared her photo. 
this is what is happening to my hands believe It Is an reaction to 
cimzia and was hoping for some feedback it blisters then bursts 
and spreads its really Itchy and hot 
Sh.ln ~nua,-.. S ilt 12:09pm 
Figure 29. SelectedAE posts from Twitter (top) and Facebook (bottom) for certolizumab. The 
post with a photograph illustrates the potential for rich data from online sources. 
Comparison 3: dimethyl fumarate (Tecfidera) 
Dimethyl fumarate is a new drug for the treatment of multiple sclerosis 
(MS), particularly patients with the relapsing form of the disease. Approved in 
March 2013, it is notable in that it is delivered via oral capsule, whereas many 
existing MS treatments require injection [91]. Like certolizumab, it is intended to 
operate on the immune system. 
As above, we present the F AERS versus MedWatcher Social cross-
comparison in Table 6. 
Dimethyl fumarate 
Symptom Spearman p 
Aggregation 
Level 
Preferred 0.37 
Term 
p-value 
0.0099 
Confidence 
interval 
[0.07- 0.61] 
Number 
of ranks 
(N) 
40 
High Level 0 .57 0.00046 [0.26- 0.77] 30 
Term 
System 0.82 o.oooso [0-46- 0.95] 12 
Organ Class 
Approximate mentions in Twitter corpus: 3,099 
Total manually confirmed AE tweets: 87 
Total FAERS counts: 15,222 
Table 6: Concordance measures between MedWatcher Social Twitter data and FDA FAERS 
reports for dimethyl fumarate, at varying symptom granularity. 
Spearman's Rank Correlation: 0.37, p = 0.0099 
500 
dlmethyllumarate (Tecfldera), Preferred Term 
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Fall 
lnftuenza like illness 
Arthralg ia 
AJooecia 
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Figure 30. Comparison ofF AERS spontaneous reports (left) with Twitter AE posts (right) for 
top reported symptoms (MedDRA Preferred Terms) associated with dimethyl fumarate. 
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Spearman's Rank Correlation: 0.57. p = 0.0046 
dimethyl fumarate (Tectlclera), High Level Term 
Therapeutic and nontherapeulic responses 
Paln and discomfort NEC 
Injection site reacUons 
Asthenic concitions 
General signs and symptoms NEC 
Rashes eruptions and exanthems NEC 
Pruritus NEC 
Joint relafed signs and symptoms 
Nousea and vomiUng sympiOms 
Circulatory collapse and shock 
Upper respiratory tract Infections NEC 
Skin and subcutaneous tissue viral infectlons 
Normal pregnancy labour and delivery I 
Muscle related signs and symptoms NEC I 
and connecuve Ussue pain and discQmfon 
Total nuJd volume decreased I 
Flatulence bJoaUng and distension I 
lnfecllous transmissions I 
Psoriatic conditions I 
I 
Coughing and associated symptoms I 
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Figure 31. Top reported dimethyl .fumarate symptoms in FAERS (left) and Twitter (right) at the 
MedDRA High Level Term level. 
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Figure 32. Dimethyl .fumarate symptom comparison by SOC. 
In this case, we see a similar pattern of concordance as with the other 
products, except that correlation is higher at the Preferred Term level. The reason 
for such higher correlation is unclear; part of the cause may be simply that we 
have limited amounts of data, with just 87 Twitter posts marked as validated AE 
posts, making the result somewhat unreliable. Notably, Drug Ineffective does not 
appear at all in the FAERS data, though it is a top complaint on Twitter. 
The clinical trials for dimethyl fumarate included over 1,500 treated 
patients (with 35,000 total patients having used it in post-marketing to as of 
early 2014 [92]). We have richer quantitative adverse event data from these 
clinical trials as compared to other products, allowing us to present a visual 
comparison of top symptoms reported from Twitter alongside the events capture 
in the trial (Figure 33). 
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Figure 33. Comparison of quantitative pre-approval clinical trial data (left) with symptoms 
identified in Twitter (right). 
Though the pattern persists of milder symptoms (Fatigue, Headache, 
Erythema [red skin]) seeing greater representation in Twitter data as compared 
to FAERS, in the examples, we do see cases of more severe symptoms reported on 
social media, including shingles, as noted below. Shingles is a clinically 
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significant reaction, and it is not currently noted in any of the product label 
information. 
O v .!. Follow 
Been dealing with intense stomach 
cramps while on Tecfidera and have 
had the worst migraines as well(l 
usually have those but not THIS bad) 
AutolmmuneMom ' ~ like Page ! 
Happy December! Question for y'ail from an autoimmune mom: 
just wondering if anyone else had a really horrible reaction to 
Tecfidera .... Four weeks of nausea, vomiting, diarrhea, headaches , 
fl ushing, and then hives ... I'll t ry anything but the allergic reaction 
was the end ... 2 days off start ing to fee l a litt le better ... any 
suggestions what to try nextm 
O v • Follow 
#tecfidera #torture this medication 
has some pretty nasty side effects, 
been suffering nausea, and stomach 
pain. #cantsleep 
Mult lpleSclerosisTalk ,C like Page 1 
Michelle asks "Now on a second chance , could you please ask the 
following; 
I have been on tecfidera for five months. Started having left sided 
numbness, tingling, sensitivity to touch and intense sharp pain. 5-
6 days later broke out In a cluster type red raised rash. It has been 
confirmed that I now have sh ingles. Neurology thinks it is because 
of the tecfidera and wants me to stop taking it at th is time. Has 
this happened to anyone else?" 
Figure 34. Sample AE posts for dimethyl fumarate from Twitter (top) and Facebook (bottom). 
These reports are somewhat more severe than what we've seen for other products, such as the 
diagnosis of hives shown on the lower right. 
MedWatcher Social: Discussion, Limitations 
Though MedWatcher Social remains a work in progress on multiple fronts, 
it already shows promise as a useful tool for extracting AE signals from social 
media. In fact, despite the limitations, the system is currently in pilot testing with 
FDA safety officials, who are collaborating on the project. Given the noisy nature 
of the data, the precision measure of 0 .67 and recall of 0.88 of our automated 
classifier make it a powerful tool. Though our analysts still face a greater number 
of daily posts warranting review than they can reasonably label, the automation 
makes their jobs easier, serving as a force-multiplier. We present in-depth 
analysis for only three medications thus far, but we have presented a 
methodology for evaluating our novel data sources against existing sources, and 
found consistent patterns across the analysis. 
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At the same time, many limitations and challenges remain. Social media 
posts necessarily represent a biased sample population, not only in that they are 
from the subset of the population that uses these tools, but also because they are 
in turn limited to those people who discuss their personal medical conditions in a 
public forum. Along those lines, another key limitation is that infrequently used 
products see correspondingly limited discussion on these forums, making it 
difficult to extract a signal. Further, because posts are for the most part not 
intended for pharmacovigilance experts, it is at times difficult to interpret their 
meaning, such as exactly what symptom a person experiencing (if any), and 
whether she is attributing it to the product in question. Because the posts are self-
reports, we further lack the more rigorous clinical indicators, such as professional 
diagnosis, lab results, etc. Exaggeration, jokes, and irony abound and are often 
difficult to discern when we pick up part of a conversation without context. 
Lastly, though we haven't yet seen any indication that malicious actors, aware of 
efforts such as ours, would attempt to "game" the system and deliberately 
generate spurious signals, we must remain vigilant to that possibility. 
Future Work 
Going forward, we see many areas of potential improvement across the 
system. First, we can potentially improve our suite of text processing algorithms 
by better tuning our hyper-parameters (such as prior probabilities, and settings 
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such as the "no symptom penalty") and improving our training data. We see at 
least two of ways of gathering improved training data (besides the active learning 
method described above): first, with more inter-rater agreement analysis, we can 
pinpoint the types of posts that analysts most often find ambiguous, and set 
consistent policies. With such studies we can also estimate an upper bound on 
the performance of the automated classifier. Second, with approaches such as 
semi-supervised learning, we may be able to target labeling to derive higher yield 
from curator efforts. Ultimately, we will also need to expand from binary 
classification to classification across all of our categories, namely, distinguishing 
Junk, Mention, Possible AE, AE, and Clinical AE. 
For the information extraction component, we will explore statistical 
methods to complement the rule-based dictionary approach, as well as 
potentially applying tools such as part-of-speech tagging to generate a richer 
feature set. Though we have the framework for assigning product-symptom 
associations manually, as yet we have no automated system for this association. 
We essentially assume that for a given post, every symptom mentioned is due to 
every product mentioned. Especially as we expand into Facebook and other 
longer-form media, addressing this problem will be essential. As regards 
symptom labeling specifically, we are working to improve our integration with 
MedDRA, expand the taxonomy, and incorporate expertise from professional, 
trained MedDRA coders. 
As noted above, our current de-duplication strategy is limited at best; we 
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will be working to parallelize the process to reduce computation time, and also 
develop a framework for performance testing against a gold standard. 
Lastly, while we have begun work on interactive visualization and analysis 
tools for MedWatcher Social, much remains to be developed so that we can, for 
example, generate the types of results presented above for individual products in 
a rapid and streamlined fashion. Still further, we are working to refine our 
analysis methods, as we continue to work to determine useful denominators, and 
identify rare but important events. 
MedWatcher Personal 
Because MedWatcher Social relies on data that is already publicly 
available, it has thus far yielded more data and more opportunity for analysis. 
However, the MedWatcher Personal system represents an important new 
paradigm for engaging consumers in pharmacovigilance and capturing previously 
missing reports. Previous studies have shown that consumer reporting, though 
currently limited in volume, improves signals as compared to purely industry- or 
clinician-originated reporting [93]. With the MedWatcher Personal application, 
we seek to amplify and better capture the consumer voice. Further, the system 
has the potential to address some of the limitations of MedWatcher Social, 
particularly as regards capturing more severe events, as well as capturing events 
people would be unlikely to reveal in a public forum. 
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System Architecture 
The architecture of the MedWatcher Personal system is illustrated in 
Figure 35. The consumer-facing app is available for iOS (iPhone, iPad, and iPod 
Touch) and Android mobile devices, as well as via Web browser, either mobile or 
desktop, at https:/ fmedwatcher.org. The app frontend is supported by a set of 
Web services allowing secure access to the user profile data, up to date news feed, 
and report submissions from the app report form. On the backend, we have 
developed a suite of tools for reviewing, approving, and submitting reports as 
they come in from users. 
Web 
end-user mobile and Web 
applications 
content feeds : news, 
FAERS/VAERS, 
MedWatcher Social 
curation and 
analytics tools 
Figure 35. MedWatcher Personal application software architecture. 
App Frontend Features 
The app frontend allows the user to create a Watch List of products of 
interest, and then view a News Feed of related safety content, including news 
media reports and adverse event reports from both other MedWatcher users and 
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as collected through FDA MedWatch, as illustrated in Figure 36. We have also 
recently begun experimenting with disseminating relevant content collected 
through MedWatcher Social, such as tweets and Face book posts relating to 
adverse events for the user's chosen products, through this News Feed feature. 
To submit a report, the user fills out a simplified version of the FDA 
MedWatch form. The form is intended to require approximately five minutes to 
complete, though the time will vary depending on the complexity of the event and 
the level of detail provided by the user. 
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Figure 36. MedWatcher Personal mobile app screens. From left, News, Watch List, and Report. 
Report triage, de-identification and submission protocol 
As soon as a report is submitted, the project team receives an 
automatically generated email notification. An administrator can then review the 
report through the secure dashboard, as pictured in Figure 37. The administrator 
assesses the report for basic plausibility and internal consistency, primarily to 
filter out test reports, jokes, spam, duplicates or otherwise clearly invalid 
submissions. If the report is deemed valid, the administrator checks the free text 
fields for any personally identifying information. If there is any, he creates an 
appropriately redacted version, and approves the report. Once the report is 
approved by an administrator, it immediately becomes available through the app, 
in de-identified form, and all users who have the product on their Watch List 
(and who have elected to receive notifications) receive an automatic notification 
that a new report has been submitted. 
AE Event AE Filed Reviewed Type Report l Product Desc. 
15 5865 6{28 / 2013 3/3/ 2014 3/ 3/ 20 14 device Essure Cramping, loss of me nstr~ Fo1 
155864 1/31/2014 3{2{2014 3/3/2014 device Essure AllergiC reaction, seve re po On 
--~- --'-- -
,:1 155863 11 / 1/ 2012 3{1/ 20 14 '3/ 2/ 20 14 I device Essu e Migraines ,pe lvic pain, pair Pe 
~ + 155862 2/ 1/ 2013 3{1{2014 3/ 1/ 2014 'device Essure I started to experience c a I w 
u 15 5861 2{10/ 20 14 2{28/ 2014 3/ 1/ 20 14 device Essure Heavy me strual bleed ing Pe• 
.:J 15 5860 12/ 13 / 201 : 2[28/ 2014 13[ 1[20 14 device E5sure I've had constanr sk in lssu blr 
0 15 5857 10 / 1/ 2009 2! 27/ 2014 2/ 27/ 2014 device Essure Rash all over my body, she Bir 
0 155856 3/3/ 20 10 2{27/ 2014 2/ 27{2014 de11 ice Essu e the right coil ept hurt ing co1 
D 15585 5 111 5/ 2010 2/ 27/ 2014 2/ 27/ 2014 device Essure Once I had the Essure put pe 
:J + 15585 4 2/ 20/ 2014 2{27/ 2014 2/ 27/ 2014 device Essure I underwe t a hysterectorr Bir 
Figure 37. MedWatcher Personal administrator tools for report review and triage. 
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In parallel, once the report is approved, the administrator then submits it 
to the appropriate government agency through the available mechanism for that 
agency. For medical device reports, we submit an automatically generated 
extensible markup language (XML) representation of the 3500 Form [13] 
through the FDA's electronic gateway. The electronic gateway has historically 
been reserved for use by pharmaceutical companies, for mandatory adverse event 
reports (Form 3500A [94]); our project is the first ever to submit voluntary 
(Form 3500) reports electronically for medical devices. For drug reports, the 
system generates a PDF of the form, populated automatically with the 
appropriate values. We then fax the PDF to the FDA's MedWatch fax gateway. 
Lastly, for vaccine reports, we use the Web form provided by V AERS to enter the 
report data. Reports are processed, approved, and submitted to the government 
typically within one business day of our receiving them. 
The user who submitted the report also receives a secure link to the 
completed report document, for his or her records. For device reports only, 
because we have access to the electronic gateway, we are also able to provide the 
users with their MedWatch report identifier numbers, allowing them to track 
their reports directly with the FDA. 
Promotion: Twitter interaction, advertising, Oprah Magazine 
To date, we have not invested substantive effort in public relations or other 
marketing to bring attention to MedWatcher; we have mostly relied on word of 
mouth and "organic" sources of traffic such as search engines. However, we have 
been running a low-cost Google AdWords campaign, drawing around 35 to 45 
visits per day at a budget of $5 per day. We also saw a burst of interest when the 
app was featured in an article in the November 2013 issue of 0, the Oprah 
Magazine [95]. Another strategy we have undertaken in an attempt to elicit 
reports is to identify adverse event reports in Twitter posts using the 
MedWatcher Social automated classifier as described above, and then contacting 
the author to suggest that they submit a report (Figure 38). To date we have 
undertaken such interactions approximately 100 times through the 
@med_ watcher Twitter handle, but only received around three submitted reports 
in response. 
Also my kidneys have been swollen ever since 
I've been on Viibryd .. but its also been super 
hot out.. 
+. Reply t."l. ReN eat * fa'o'OI'I!e ... More 
4:37PM · 24 .un 13 
_ ~c 4 ~ 
~ noticed you're having: an issue with 
Viibryd. med_wa1cher invites you lo notify the US_FDA: 
tinyu11.comlldclek3 
Details .. Rep cL1. ~ e.;~ * Favon:e ••• More 
Figure 38. We use MedWatcher Social to identify posts of interest, then solicit reports via the 
@med_watcher Twitter account. 
In order to better understand our existing user base, with the hope of 
better targeting our outreach efforts and eliciting more participation, we 
conducted a brief survey of users, an excerpt of which is shown in Figure 39. 
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Are you a health care worker?* 
rJ No 
.-·i Doctor 
r =) Nurse I Nurse Pract itioner 
,- P·harmacist 
,.::_, Qt:her: 
Are you a caregiver to others?* 
Responsible fm care for someone bes ides y.ours elf 
0 No 
0 Parent 
;'-) Child 
Other: 
Do you take daily medication?* 
(exclude ·dietary supplements) 
Figure 39. MedWatcher Personal user survey. 
MedWatcher Personal: Analysis Methods 
As with MedWatcher Social, we present both examples of individual 
reports of interest, and a quantitative aggregate analysis. We show examples for 
several different products and conduct a comparison analysis for the Essure 
medical device, the only product for which we received sufficient report volume 
to enable aggregate analysis. Where we present individual example reports, in 
some places we cut out sections of text for brevity (indicated by ellipsis notation), 
and remove personally identifying information, but otherwise leave the original 
text verbatim, including all typographical errors, abbreviations, and so forth. The 
MAUDE reports are edited by the FDA to remove key dates and other potentially 
identifying information, indicated by "[redacted]" in the report text, but 
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otherwise similarly left intact. In the aggregate analysis, we again face the 
challenge of matching symptom categories across different data sources. In this 
case, we actually integrate four different sources of safety information: the 
product label (clinical trials), the MAUDE reports collected by the FDA, the 
MedWatcher Personal direct reports collected through end-user the application, 
and the Twitter data collected through MedWatcher Social. 
MedWatcher Personal: Results 
User Statistics, Report Volume 
We currently have over 6,6oo registered users, and just under 1,000 who 
have used the system in the past 30 days. Since the launch of the current version 
in February 2013, we have received 550 plausible non-duplicate reports, as 
broken down by product in Table 7. 
As regards our Google AdWords campaign, notably, thus far we are seeing 
high click-through rates on search terms such as "side effects of drugs," with 
some over 4%, whereas typical rates are 1-2%. The high click-through rate 
indicates there is demand for the service and potential to reach a much larger 
audience as we ramp up. 
To date we have emailed the user survey to approximately 1,300 registered 
MedWatcher users and received 81 responses, for a 6% response. Respondents 
skew toward the older and female demographic, with 64% aged 45 or older and 
65% women. As expected, they are likely to be medication users, with 74% taking 
a daily medication. Finally, respondents appear to have positive regard for the 
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system, with 66% reporting that they would either "likely" or "absolutely" 
recommend MedWatcher to a friend. 
Products Number of Reports 
Actemra, Actonel, Adderall, Ambien CR, 1 
amlodipine besylate, amphetamine sulfate, 
anastrozole, Aricept, atenolol, Augmentin 200, 
Avelox, bipolar lead, Byetta, Celexa, 
ciprofloxacin, clarithromycin, clindamycin 
hydrochloride, clonazepam, Cymbalta, 
Daytrana, Demerol, Depakene, Depakote, 
Depo-Provera, doxycycline, Edarbi, Evista, 
fexofenadine hydrochloride, Flomax, Fluarix, 
fluoxetine hydrochloride, Fluzone, furosemide, 
gabapentin, Glucophage, Herceptin, 
hydralazine hydrochloride and 
hydrochlorothiazide, ibuprofen, Imitrex, 
infusion pump syringe, Levaquin, Lidoderm, 
lisinopril, lithium carbonate, loratadine and 
pseudoephedrine sulfate, Lovenox, MMR II, 
Multaq, Paxil CR, Plavi.x, pravastatin sodium, 
prazosin hydrochloride, prednisone, Prilosec, 
Protopic, Qsymia, reserpine, Seasonale, 
Seroquel, Skyla, Topamax, tramadol 
hydrochloride, Viib1yd, Vyvanse, Xarelto, 
zolpidem tartrate 
Aetas, allopurinol, amoxicillin, Effexor XR, 2 
metformin hydrochloride, Neurontin, 
NuvaRing, oxcarbazepine, Ritalin, trazodone 
hydrochloride, Zostavax 
atorvastatin calcium, Enbrel, Tecfidera, Zyrtec 3 
Abilify 4 
Mirena 6 
Essure 441 
Total reports, including test, duplicate, and unintelligible, since launch in February 2013: 752 
Totalapproved:sso 
Table 7· Summary of reports received through theMedWatcher Personal application. 
Key Sample Reports 
Ambien CR (taken with Xanax), male, 23: 
"Difficulty Breathing" 
zolpidem tartrate, sex not specified, 62: 
"noctambulism resulting in a fall on concrete floor. Cracked pelvis, severe 
contusion. 2 month recovery." 
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Though we only have two reports for zolpidem, they fit the pattern of more severe 
events appearing in direct reports as compared with social media. In the F AERS 
data, "Respiratory Arrest," the closest symptom match for "difficulty breathing," 
is present, but ranked near the bottom with approximately 100 reports. 
Meanwhile, as noted above, sleepwalking is a well-known side effect of zolpidem, 
seen primarily in the F AERS data but also in social media data. 
Tecfidera, female, 36 (reported September 2013) 
"In the first month of use, I experienced two or three episodes of 
flushing, stomach pain, and some heartburn. Provided I take the 
medication after a meal, these issues had all resolved by the second 
month." 
Tecfidera, female, 36 (same user, reported January 2014) 
"Stomach cramps, bloating, and skin flushing (face and neck)" 
Tecfidera, female, 35 
"After a month of taking Tecfidera I had a leg weakness that was getting 
worse every day [ ... ]. I couldn't walk more than a few steps. I thought I 
was having another MS attack. I went to the emergency, got steroids and 
started to bounce back. I started Tecfidera again and two days later leg 
weakness was coming back. I went back to the hospital to continue my 
steroid treatment [ ... ] I was doing fine again until I started Tecfidera. 
The next morning I had a terrible burning and numbness in my legs, 
arm and leg weakness. Balance was off. I am 100% sure this drug caused 
me to either have another attack or made it worse!" 
The first two dimethyl fumarate reports are consistent with the milder effects 
found in social media reports. The third report raises legitimate concert, 
especially given that the user asserts that the symptoms stopped when she 
stopped taking the drug, then restarted when she resumed taking it. 
Casodex, male, 87 
"Dx: metastatic prostate cancer and spinal cord compression 
Tx: Casodex (bicalutamide) 50mgjday 
LFfs normal at initiation of therapy 
AE: Fulminant hepatic failure after 3 weeks of therapy (synthetic fx preserved, but 
jaundice and transaminitis) 
Death 5 weeks after initiation of therapy 
Death certificate only lists prostate cancer as COD 
Pt was my father. I am a NP." 
The report, from a 2010 version of the MedWatcher mobile app, is of a previously 
suspected but rare side effect, hepatic failure. Although the reporter is a clinician, 
the patient was his or her father, and the report explicitly states that the event 
was not reported through a clinical reporting mechanism ("Death certificate only 
lists prostate cancer as COD [cause of death]"). 
Prilosec, female, 38 
"trouble breathing, trouble swallowing, and blood/mucus in stool" 
None of these symptoms is listed in the label information, except potentially what 
the label lists as "fecal discoloration" being mistaken for "blood/mucus in stool." 
Mirena, F, 31 
"Kept having a lot of aches and pains in my abdomen for about a month. Called my doctor 
several times and the office kept saying that it was normal [ ... ]. I had it for about a year when all 
this happened, so I didn't feel like it was normal. I woke up in the middle of the night because I 
had a sharp pain. Stood up and blood was all over my pants, passed out and when I came to I was 
in so much pain I couldn't walk. [ ... ]was vomiting. Called 911 and the ambulance picked me up. 
My stomach was distended like I was 6 months pregnant. Ended up being two abcesses from an 
infection caused by the Mirena and they ruptured spreading the infection all in my abdomen 
through my intestines. Had emergency laparotomy because of it and a hospital stay of 7 days. [ ... ]" 
This report for the Mirena intrauterine device is notable for its severity, with the 
adverse event resulting in hospitalization, again consistent with the pattern of 
direct reports having greater severity. 
Effexor XR, female, 38 
"I decided to taper off Effexor XR 150 mg I had been on for three years after vomiting 
every morning, fringing teeth and horrific spikes in blood pressure. I experienced horrific shocks 
in my brain that shit down my right side.[ ... ] I had a think was a seizure. I[ ... ] almost drowned in 
my bathtub from seizing in it. [ ... ] I lost at least 15% strength on my v right side and my knee 
swells so bad I can only walk for a half hour at a time. This has made me manic, suicidal, self 
hurting and seasonal allergies. [ ... ]" 
Aside from the seizure event, severe in itself, a key element from this report is the 
suicidal thoughts. Effexor XR is a serotonin and norepinephrine reuptake 
inhibitor (SNRI); suicidal thought is a known side effect of selective serotonin 
reuptake inhibitor (SSRI) drugs and SNRis share some physiologic mechanisms 
of action with SSRis. 
Vyvanse, male, 23 
"I took my Vyvanse dose (somg) in the morning and began to develop extreme thirst 
approximately 3-4 hours after taking the medication. I developed a throbbing pain in my temples, 
felt dizzy, itchy, and my tongue felt sore. I took my blood pressure and it was 141/99 mmHg. My 
pulse was 124 bpm. I have drastically increased my fluid intake and have taken my blood pressure 
medications. I feel that it's important to mention that last night was the first prescribed dose of 
Ranitidine that I've taken. I am wondering if because my stomach acid was more neutral, the 
Vyvanse was able to hit me stronger than it ever has. I used to be on Adderall XR 30mg per day 
and never had an issue like this one." 
Though this event is milder than most of the others listed, it is notable for the 
detail provided; the user reports a detailed sequence of events along with clinical 
indicators, namely, blood pressure and pulse readings. 
Essure Case Study: Background 
Essure is a medical device used for permanent birth control for women. It 
consists of metal coils composed of nickel and polyethylene terephthalate (PET) 
fibers, implanted in the fallopian tubes through a transcervical procedure (Figure 
40). Following the procedure, tissue grows around the coils, serving to block the 
fallopian tubes and thereby prevent pregnancy permanently. Developed by 
Conceptus initially in 1998, Essure was approved in the US in 2002. Given that 
one fifth of married women who use birth control opt for some form of 
sterilization, the market for the product is potentially massive [96]. The current 
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prevailing option for permanent female sterilization, tubal ligation, is considered 
major surgery and requires general anesthesia, even when done laparoscopically. 
The surgery carries risk of infection among other risks, and requires up to one 
week of recovery time. By contrast, the Essure label information asserts that "you 
can go home 45 minutes after the procedure," and promises recovery within one 
or two days. Patients then require a hysterosalpingogram (HSG) test three 
months later to confirmation blockage of the tubes. In terms of effectiveness, 
tubal ligation one year failure rate is estimated at 0.5% [97] ; Essure failure rate is 
a reported 0.27% over five years [98] . Essure thus ranks as among the most 
effective birth control methods of any kind available on the market. 
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Figure 40. The Essure coil and its deployment and functioning. (Image copyright Conceptus, 
Inc., retrieved from Wikipedia [gg].) 
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Over the past decade, researchers have conducted a number of studies of 
Essure and its effectiveness and safety. Basinski compared Essure with Adiana (a 
similar device no longer available) in 2010 [100], reporting zero pregnancies in 
the trials and minimal adverse events, including a 1.1% perforation rate. Nickel 
allergy is not cited as an issue, though page 8 cites the nickel free Adiana as a safe 
alternative for patients with documented nickel allergy. In another study 
published in 2009 [101], Palmer and Greenberg report that in trials, 100% of 
women were satisfied with their recovery from the procedure at 90 days follow-
up, and in trials, no major adverse events occurred. Palmer and Greenberg also 
note that a review of MAUDE reports from 2002 to 2009 revealed no major 
adverse events; the thesis author preformed a cursory review of Essure MAUDE 
reports received in 2008 and found multiple reports indicating nickel allergy 
symptoms, and one ectopic pregnancy [102]. The 2009 Palmer and Greenberg 
study notes that Essure is contraindicated for patients with known nickel 
sensitivity by skin testing. 
In 2010, Olympic skier Picabo Street served as a paid spokeswoman for 
Conceptus, announcing she had had the Essure device implanted and endorsing 
the product. Street subsequently became pregnant, though Conceptus claimed 
that the pregnancy occurred prior to the required HSG confirmation test [103, 
104]. In 2013, Conceptus, with $140 million in annual revenue, was acquired by 
Bayer for $1.1 billion [105, 106]. Given the potential size of the market, the size of 
the acquisition indicates it is likely that Bayer plans large-scale marketing of 
Essure in the near future. The product Web site currently indicates that the 
company has sold over 750,000 Essure units [107]. Overall, based on both pre-
approval and post-marketing research, the device appears to be generally safe 
and effective, though questions remain in specific individual cases. 
Characterization ofEssure MedWatcher Personal and Social 
Reports 
At the time of writing in March 2014, to date we have received 440 Essure 
adverse event reports through the MedWatcher Personal application, with more 
coming in each day. We manually coded approximately 400 of these reports into 
203 symptom categories. In the interest of rapid analysis, and because we lack a 
certified MedDRA coder, these categories are not formally linked to any standard 
medical dictionary, though they roughly correspond to MedDRA Preferred Terms 
in terms of granularity. The top reported symptoms are listed in Table 8, with a 
few example reports below. With the application, users have the option to 
complete a profile, including their home address, giving us some geographic 
information for these reports. Of the 400, around 85 included some geographic 
information; we show a map of the nationwide distribution of the reporters in 
Figure 41. 
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Symptom Reports 
pam 390 
excessive menstrual 199 
bleeding 
back pain 153 
fatigue 138 
uterine cramping 135 
bloating 133 
abdominal pain 133 
headache 132 
pain (pelvis) 115 
irregular period 90 
weight gain 90 
pain during sex 82 
m1grame 81 
hair loss 71 
nausea 63 
joint pain 63 
hysterectomy 6o 
dizziness 6o 
depression 6o 
emotional instability 58 
fogginess 51 
rash 46 
pain (hip) 45 
nickel allergy 45 
blood clot 45 
numbness 44 
anxiety 43 
swelling 42 
forgetfulness 42 
tingling 41 
insomnia 38 
metallic taste 36 
vision problem 36 
pain (leg) 34 
acne 32 
device moved 30 
Table 8. Top symptoms reported for Essurefrom the 400 MedWatcher direct reports. 
Female, 30: 
"Migraines, heavy menstural periods with large clots, pelvic pain, hip pain, dizziness, 
anxiety/ panic attacks,skin problems, back pain, bleeding after sex, painful sex, body aches, joint 
pain, bowel issues, chest pains, brain fog, cramping, longer periods,discharge,dizziness, dry 
skin,fatigue,hip pain,mood swings,muscle spasms, neck pain, bloating, teeth issues, vibrating 
sensation in lower abdomen,numbness in extremities" 
The large number of Essure reports makes it difficult to choose a single 
representative, but this example is typical in that encompasses the raft of 
common symptoms. Besides these symptoms, many of the reports include 
mentions of a "metallic taste" in the mouth, and nickel allergy or sensitivity. 
Male, 36: 
"[ ... ] For the entire time she was implanted with essure every single time we had 
intercourse we both became very ill. I had a rash and raised bumps on my penis after intercourse. 
There was a time that the bumps just stayed and did not go away. She and I experienced vomiting 
and diarrhea immediately following intercourse. The rash I experienced was irritated, burned, 
and itched. [ ... ]We were tested for every std you can think of. All being negative. After her 
hysterectomy and removal of Essure device we have not had a problem with rashes, bumps, or 
illness following intercourse. She has been Essure free since April of 2013. I purposely waited 
almost a year before filing to make sure that these effects would not resurface. As they have not it 
leads me to believe that this was a series of isolated events caused by essure." 
This report is an outlier in that it is the only one submitted by a male user. We 
include it here simply to illustrate that adverse effects can extend beyond the 
original patient in a variety of ways. 
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Figure 41. Map representing the location information provided in 85 of the 400 Essure reports, 
showing the national scope of the MedWatcher user community. 
In MedWatcher Social, we have over 500 labeled AE tweets for Essure, 
with the top symptom categories listed in Table 9 and selected sample tweets in 
Figure 42. In both sources, several patients highlight sensitivity to nickel as a 
condition and potential cause for their symptoms. 
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Symptom Count 
Pain 164 
Hysterectomy 72 
Pregnancy 74 
Nonspecific reaction 67 
Device malfunction 54 
Malaise 27 
Drug ineffective 24 
Abdominal distension 21 
Haemorrhage 17 
Allergy 15 
No Symptom Identified 14 
Headache 14 
Abdominal pain 14 
Fatigue 13 
Allergy to metals 13 
Rash 10 
Arthralgia 8 
Nausea 9 
Weight increased 9 
Pelvic pain 8 
Table 9. Top symptoms reported in Essure AE tweets. 
@Bayer thought u would like 2 know: it 's 1 :37 am, I have to be @ work @ 7:30, 
&a ' ~c & legs r t' .. rtin so bad be of #Essure I can't s e . 
I'm Essure vict im & Essure survivor. I lost two years of my life because of the 
horrific fac s I endured f rom Essure. Get another BC! 
"@ ::-:a: me too. ceellike I'm dying . lm e c to them and nobody will get 
#essure outta me! 
Feeling liKe crap! Have a cough & thanks to #essure ..,aving to wear liners so I don't 
wet mysel . Sorry for tmi just spreading awareness. 
Figure 42. Typical tweets regarding adverse events attributed to Essure. 
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Characterization ofEssure FDA .MAUDE Reports 
The FDA MAUDE data for Essure to date include several hundred reports; 
for this study we selected 129 reports from 2012 and 2013. We then manually 
coded these into 153 symptom categories, many of which overlapped with the 
categories identified through labeling of the MedWatcher Personal reports. 
Across MAUDE and MedWatcher Personal we thus saw a total of 260 distinct 
symptom categories with at least one mention, of which 64 had at least 3 
mentions in both MedWatcher Personal and MAUDE. Though the MAUDE 
reports show high concordance with the MedWatcher Personal reports as shown 
below, they also included a number of clinician-originated reports, generally 
pertaining to issues with the procedure, or the condition of the device itself in its 
packaging. Top symptoms are listed in Table 10 along with sample reports in 
discussed below. 
Symptom Count 
pam 90 
excessive menstrual 37 
bleeding 
hysterectomy 34 
procedure problem 33 
device moved 33 
irregular period 26 
abdominal pain 26 
salpingectomy 22 
uterine cramping 20 
back pain 20 
weight gain 18 
headache 17 
dizziness 17 
perforation 17 
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pain (pelvis) 16 
fatigue 16 
pain during sex 15 
pregnancy 15 
m1grame 14 
device damaged 12 
nausea 12 
bloating 12 
nickel allergy 12 
joint pain 12 
device removed 11 
tingling 11 
numbness 11 
depression 10 
vision problem 10 
fogginess 10 
device embedded in 10 
uterus 
Table 10. Top symptoms reportedfor Essurefrom the 129 MAUDE reports from 2012 and 2013. 
"On [redacted] 2011, I had Essure coils placed for sterilization purposes. [redacted] later, I 
developed a new onset migraine headache. Never experienced a migraine before. In the weeks 
following, I developed numbness/tingling in my extremities, cognitive fog, blurred vision, balance 
issues, and deep bone pain. Initial MRI of my brain showed white matter changes[ ... ] I was told 
with '99% certainty' that I have multiple sclerosis. [ ... ] I developed right sided abdominal pain and 
met with my ob. [ ... ]I underwent the hysterectomy on [redacted] 2012. As of today, [redacted] 
2012, I no longer suffer from the above mention neurological issues or from the abdominal pain. I 
believe that I had a adverse reaction to the Essure coils." Event date 12/9/11, MDRFOI_ID 
2664479· 
The symptoms related in this report typify many of the reports captured in 
MAUDE, though the MRI procedure and (erroneous) diagnosis of multiple 
sclerosis is uncommon if not unique. 
"I was implanted with the stop device (now marketed as Essure) in 2000. I was part of the study 
group and [ ... ] complained of pain and other issues. These issues were dismissed by the study 
staff and I was told that I must have another health issue and that my complaints were not related 
to the device. Now, 13 years later, [ .. . ] I am having a hysterectomy to remove the implants. I suffer 
from wildly erratic, irregular periods, pelvic pain that is nearly constant, sharp stabbing pains in 
the pelvis regions, headaches, symptoms of severe allergic reaction from an unk source 
(presumably from the nickel and/or pet fibers), widespread severe swelling, extreme fatigue, 
muscle pain and weakness, muscle spasms and tremors." Event date: 9/16/13, MDRFOI_ID 
3362434· 
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The above report is from a patient who participated in a pre-approval trial for the 
device. The allegations that her concerns were "dismissed" by the study operators 
are difficult to prove at this point, but if true, represent a grave violation of 
protocol. 
"The medical opinion of the attending physician was that the cause of death was not directly 
related to the Essure inserts or procedure. Patient had Essure procedure [redacted] 2013. [ ... ] On 
[redacted] 2013 patient went to emergency room with abdominal pain. Dr [redacted] (who was 
not the implant doctor)[ ... ] found the patient's cervix, fallopian tubes and uterus were necrotic. 
[ ... ]patient tested positive for group a strep infection. On [redacted] 2013, patient went into renal 
failure and die, patient passed way. On [redacted] 2013, Dr [redacted] stated blood cultures were 
positive for group a strep and he believes the cause of death was related to necrotizing group a 
streptococcus infection [ ... ]."Event date: 8/26/13, MDRFOI_ID 3369777. 
This report is an outlier in that it reports a death associated with Essure, though 
the official determination is that the death was not caused by the device. 
"Patient was undergoing 'hysteroscopy and Essure placement and polypectomy.' Cervix was 
dilated and hysteroscope was introduced. Both tubal ostia were visualized. The first Essure was 
placed in the right tube. The coil snapped in half and was not well-deployed. The pieces of the first 
attempted Essure that broke were retrieved and will be sent to the company for their analysis. A 
second Essure coil was placed in right tube with 4 visible coils. Another Essure was then placed in 
the left tubal ostium without complication with four coils visible. The hysteroscope was removed 
and Randall Stone forceps were introduced to remove remaining pieces of polyp. A second 
attempt to remove the remaining pieces of polyp picked up the displaced Essure from the right 
tubal ostium. This was removed the Randall Stone forceps and was not saved. The hysteroscope 
was reintroduced. No coil was in the right tube. A third Essure coil was placed in the right tube. 
Presence of both coils were verified before withdrawing hysteroscope. Patient to return for 
confirmation ofEssure coils in 3 months.'' Event date: 11/14/12, MDRFOI_ID 2892102. 
This report of a clinician encountering procedural problems with the device 
implantation is typical of the clinical reports found in MAUDE. In this case, no 
adverse impact on the patient is noted. 
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Comparison of Essure Reports Across the product label, MAUDE, 
MedWatcher Personal, and MedWatcher Social 
The Spearman's rank correlation between the MedWatcher Personal and 
MAUDE reports for Essure, across the 64 symptom categories with 3 or more 
reports, is 0.65, p-value 1.0 x lo-s, CI: [0-48- 0.77]. Given that the analysis is at 
high granularity of symptom category (roughly equivalent to Preferred Term), 
this concordance is quite strong. The two sources are similar in nature in that 
they include detailed patient-level reports, and both actually end up in the 
MAUDE repository (though, due to the timeline of MedWatcher report 
submission to the FDA, we know there are no actual MedWatcher reports 
represented in the MAUDE data). However, when we launched the MedWatcher 
app, we had little indication as to whether we could ever collect sufficient valid 
reports for any product to allow us to conduct this type of analysis. The volume of 
reports and high concordance represents a major validation of the app as an 
important tool for consumers and a first step in filling the massive 
underreporting gap currently seen with the FDA MedWatch/F AERS and CDC 
V AERS systems. 
To complete the analysis, we also compare the MAUDE and MedWatcher 
breakdowns with the soo tweets collected and labeled through MedWatcher 
Social. For the MAUDE-MedWatcher Social comparison, we find 21 overlapping 
categories, with correlation of 0.31, p-value: o.o8, CI: [-0.14- o.6s]. Though we 
don't reach significance, the result is still notable, given that the comparison is at 
the Preferred Term level. For the MedWatcher Personal-MedWatcher Social 
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comparison, we find 26 overlapping categories, with correlation 0.25, p-value: 
o.n, CI: [-0.15- 0.58]. We again fail to reach statistical significance, but find 
some degree of concordance, lending validity to these top-reported symptom 
categories. 
For our last comparison, we examine the clinical trial information as 
presented on the product label. Unfortunately, as we have seen with the drug 
products discussed above, the label offers limited quantitative adverse event 
information. However, the current consumer label does list chronic pelvic pain, 
device migration, pregnancy, ectopic pregnancy, and nickel reaction (rash, 
itching, hives) as potential long-term adverse events associated with the device 
[98]; the clinician-facing label lists 10% or higher prevalence of cramping, pain, 
nausea and vomiting "resulting from the placement procedure" (indicating that 
these symptoms are temporary) and 3% or higher prevalence of back pain, 
abdominal pain, and pain during sex during the first year following implantation 
[107]. Symptoms not on the label that appear consistently in the reports include 
chronic excessive menstrual bleeding and clotting, chronic fatigue, uterine 
cramping, bloating, irregular periods, weight gain, nausea, all of which are top 
symptoms from the MedWatcher Personal reports as well as the MAUDE reports. 
Regarding the issue of nickel sensitivity, studies indicate that nickel is a 
top allergen, with 17% of women allergic or hypersensitive [108]. A skin patch 
test for nickel allergy requires a dermatologist to perform the initial patch 
placement and assessment two to four days after placement. We have no way of 
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measuring the number of women who are candidates for Essure but are 
subsequently refused the device due to positive nickel allergy, but thus far none 
of the reports, across MAUDE, MedWatcher Personal, and MedWatcher Social, 
mention the patient being given a nickel sensitivity skin patch test prior to 
implantation. 
Though the cross-comparison presents challenges in appropriately 
matching "apples to apples" across disparate sources, to our knowledge, our 
analysis is the first to integrate these sources for a comprehensive view of post-
marketing safety information for a medical product. As noted above, it is not the 
aim of our work to reach a recommendation, from a regulatory standpoint, as to 
whether a given product should be removed from the market. Further, due to the 
nature of the data sources, we don't have a reliable method for establishing the 
true number of people who have had the device successfully implanted with no 
problems, nor the number who have experienced these symptoms. As noted 
above, given the large demand for permanent birth control, and the apparent low 
risk of the product as compared to its alternatives, Essure offers important 
benefits. However, taken together, our results show risks for serious adverse 
events. At the least, both patients and clinicians should be alerted to these risks, 
not only before the patient undergoes the procedure, but also for cases when a 
patient presents with a raft of similar symptoms with no clear cause. As noted in 
several of the reports, because it is a new product, many clinicians are unfamiliar 
with Essure and thus have difficulty diagnosing and treating patients who may be 
suffering from adverse effects. Lastly, as with vaccines and other products that 
come with risks, yet benefit the public's health overall, officials could consider 
financial compensation for those who experience severe negative outcomes. 
MedWatcher Personal: Discussion, Limitations 
As noted above, except for Essure, we've seen only a limited number of 
reports, making it difficult to perform any analysis beyond qualitative assessment 
of individual reports. However, we are seeing positive feedback on the system; 
users find it generally easy to use and an improvement over the existing 
MedWatch Web site and paper forms. One gap in our assessment is that we don't 
know how many of the reports we received through the app were also submitted 
separately by the user through MedWatch. Based on our initial interactions with 
the online community around Essure, we suspect that some of these reports have 
also been submitted directly to the FDA through their traditional channels. 
However, on the positive side, as noted above, thus far we have seen more 
severe events reported through the app. This severity bias represents a potential 
limitation, but if we couple the direct reports with the milder events observed in 
social media, a more complete picture emerges. 
Thus far, perhaps the biggest challenge for MedWatcher Personal has been 
in spurring user adoption of the system. The limited number of registrations and 
reports is certainly due in part to our lack of promotional efforts. However, we 
still see that users register, but then never return, or never submit a report. We 
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suspect that users don't necessarily view their adverse event experiences as 
severe enough to warrant a report, or else they assume that clinical systems are 
already capturing their experiences. We also face a "chicken-and-egg" problem 
where users see few existing reports and so have little motivation to participate. 
We've attempted to address this issue by incorporating reports from the F AERS 
and MAUDE systems, but they are difficult to extract and updated only 
infrequently. 
For the professional clinical community, MedWatcher also represents a 
potentially valuable tool for meeting reporting obligations as well as informing 
the public and regulators of adverse events. While we have a few reports from 
clinicians, we have thus far seen only very limited engagement by this 
community, and the comparison of Essure MAUDE reports with MedWatcher 
reports shows that the missing clinical experiences represent a gap in our data 
collection. While the focus remains on engaging consumers, future work will 
include efforts to spur adoption by clinicians as well. 
As with MedWatcher Social, we also face biases in the user population and 
the challenge of establishing appropriate denominators and other factors for 
evaluating reports. 
Future Work 
Beyond expanding our efforts to spur adoption, we are pursuing a range of 
avenues of improvement to MedWatcher Personal. We are working to offer a 
100 
more intuitive user experience, incorporate simplified and more useful product 
information screens, to spur more users to add products to their Watch Lists, and 
make reporting still easier. On the backend, we have not yet seen sufficient 
volume to warrant an investment in automated processing of the submissions, 
but as we ramp up, we may need to incorporate some form of automated triage. 
We have already taken initial steps to integrate MedWatcher Social data into 
MedWatcher Personal; we envision further expansion of these efforts, allowing 
consumers to gain insights into product safety issues from social media, 
potentially establishing a feedback loop of reporting. Lastly, for analysis, and as a 
benefit to the user community, we will need to develop a protocol for applying 
MedDRA codes to the submitted reports, and disseminating aggregate results 
alongside the individual submissions we display currently. 
In addition to these features and improvements, we have found there is 
not only national but also global demand for improved consumer AE reporting: 
we have begun work with the European Medicines Association (EMA) Innovative 
Medicines Initiative (IMI) to expand MedWatcher Personal to the European 
Union. This internationalization effort will be a central area of future work for the 
project. 
Conclusion, Contributions of the Thesis 
Overall, the key contributions of the thesis fall in two areas. First, we have 
engineered two novel systems for pharmacovigilance, and shown their viability. 
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Specifically, with MedWatcher Social, we have created a data acquisition 
framework and coupled it with strong information extraction and document 
classification algorithms. The system incorporates rich product and symptom 
taxonomies, linked to each other and valuable in themselves, serving to map 
informal language to formal structures. We have further created a scalable 
framework for incorporating and tracking arbitrary new products and symptoms 
indefinitely beyond these initial efforts. We have also taken initial steps to create 
a structured taxonomy of quantitative data from pre-approval clinical trials, and 
link it to our product and symptom taxonomies. Though others have taken steps 
to created structured product label data [109], to our knowledge, no such 
repository of ranked adverse events exists currently. 
In parallel, with MedWatcher Personal, we introduce a new paradigm for 
consumer and clinician direct reporting, contrasting the existing cumbersome 
procedures with rapid, easy-to-use tools available across the common consumer 
device platforms. Though the total volume of reports over the study period has 
been low for products other than Essure, the examples represent the types of 
reports we hope to receive and the potential of the system. And while the 
percentage of plausible reports could certainly change as we scale up, for the 
moment, we also show that we are not overloaded with spam reports. 
Secondly, from these systems, for four medical products, we have 
demonstrated both concordance of signals derived from our novel data sources 
with traditional sources, as well as identifying and characterizing key differences. 
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Specifically, though we see significant overlap in symptom categories between 
Twitter posts and FDA spontaneous reports, especially at the broader groupings, 
we find that less severe events are enriched in Twitter. For the Essure medical 
device, we present the first cross-comparison of four distinct data sources, 
namely, pre-approval trial reports, MAUDE spontaneous reports, MedWatcher 
Personal reports, and Twitter posts collected through MedWatcher Social. 
Despite the tremendous benefits of modem medicine, history is littered 
with examples of unsafe products, their true nature understood too slowly, pulled 
too late from the market, costing too much suffering and too many lives. 
Unfortunately, there is no easy solution. But we can do better. With the research 
introduced in this thesis, we open a new window to understanding medication 
safety in post-marketing, one small step towards making drugs, devices, and 
vaccines safer. 
Disclosure 
I own shares in, and consult to Epidemico, a company working to commercialize 
some of the work described in the thesis. 
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Appendices 
Explanation of Fisher-Robinson and Naive Bayes classifier methods 
We start with a description of a Naive Bayes classifier, then present a 
description of the Fisher-Robinson classifier, pointing out similarities and 
differences as we go. In both cases, we focus on the binary document 
classification task, where we seek to assign a novel document to either "adverse 
event" or "NOT adverse event," based on a set oflabeled training examples. In 
both cases, we are performing two basic actions: first, we must compute a 
probability value for each word in the document (i.e., the probability that a 
document containing the word belongs to the class "adverse event"); second, 
because the document contains more than one word, we must combine these 
probabilities into a single indicator value which will allow us to assign the 
document to the most likely class. 
Naive Bayes [no]. The value we seek to determine is the probability that 
the document D belongs to the class "adverse event" (A), i.e., P(AID). As noted, 
the first step is to determine a probability value for each word in the document, 
represented as the probability of word Wi given the class A: 
P(wi n A) 
P(wi lA) = P(A) 
We calculate this probability based on the observed examples. Namely, the 
numerator of the above fraction is equal to 
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number of AE examples containing wi 
number of examples 
While the denominator is equal to 
number of AE examples 
number of examples 
Canceling "number of examples," we then have 
number of AE examples containing wi 
P(w·IA) = ------------~ number of AE examples 
We then assume that the words occur independently, and combine the 
probabilities by multiplying them. So we can then represent the probability that 
document D contains all the words, given class A, as: 
(1) P(DIA) = [1 P(wi lA) 
i 
Thus we combine the probabilities by multiplication. But we still need to 
determine P(AID). By definition, we have 
P(A n D) 
(2) P(DIA) = P(A) 
P(A n D) 
(3) P(AID) = P(D) 
From Bayes' Theorem, which states that given arbitrary events A and B, 
P(AIB) = P(BIA)P(A) 
P(B) 
We can rewrite (3) above to yield 
P(AID) = P(DIA)P(A) = P(A) * P(DIA) 
P(D) P(D) 
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P(DIA) is given by (1), so we can substitute, yielding 
P(A)n (4) P(AID) = P(D) . P(wiiA) 
t 
Because "adverse event" (A) and "not adverse event" (~A) are disjoint, we 
equivalently say 
P(A)n (5) P( -AID)= P(D) . P(wii-A) 
t 
We then divide (4) by (5), yielding 
P(AID) P(A) n P(wdA) 
P( -AID) - P( -A) . P(wd-A) 
t 
We then have our indicator value; for convenience, we take the logarithm of both 
sides of the equation, yielding 
P(AID) P(A) "" P(wdA) 
ln P( -AID) = ln P( -A)+ 4 ln P(wd-A) 
t 
If the value is greater than o, then we place the document in the "adverse event" 
class; otherwise, we place it in the "not adverse event" class. 
Robinson Classifier [111]. As before, we need to compute a probability 
value for each word w in the document. We start with 
• b(w) =(no. of AE examples containing w) I (no. of AE examples) 
• g(w) =(no. ofnon-AE examples containing w) I (no. ofnon-AE examples) 
We can then compute a basic probability value p(w) as 
(w) = b(w) 
p b(w) + g(w) 
106 
However, the limitation here is that it does not take in to account the fact that we 
may have a small or large number of AE examples containing w, and a small or 
large number of non-AE examples containing w. Our belief in the probability 
value should be stronger when we have a greater number of examples. In order to 
capture the number of examples, instead of using p(w) as above, we define f(w) as 
(s * x) + (n * p(w)) f(w) = ___ s----:..+_n _ ....:... 
Where s and x are model hyperparameters, with s representing the "strength" we 
assign to our a priori assumption, namely, x, which represents our a priori 
assumed probability of the "adverse event" class for a completely unknown word. 
Meanwhile n represents the number of training examples we have for the word. 
Note that when n = o,j(w) = x. 
Our next step is to combine the individual probabilities into a single 
indicator value. Here, instead of assuming independence and multiplying the 
probabilities together, we combine them using Fisher's method for combining 
probabilities [112], namely: 
X 2 = -2ln n f(w) 
w 
This result is now X2 , or a "chi squared" distribution with 2n degrees of freedom, 
where n represents the number of words in the document; to compute the 
combined probability, we apply the inverse chi-squared function, C-1 
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def C 1 (chi , df ) : 
m = chi I 2 . 0 
sum= term = math . exp (-m) 
f ori in r ange (l, df I 2 ): 
term *= m I i 
sum += term 
return sum 
So we then define Has 
H = c-1 ( -2ln n f(w), 2n) 
w 
We can also take 1 - j( w) as the individual probability of "not adverse event" for 
each w, and compute another indicator, S, as 
s = c-lc -2ln n 1- f(w), 2n) 
w 
Finally, we combine the two indicators to yield J: 
1+H-S 
/=----
2 
The value I will be a real number ranging from o to 1; with o indicating "not 
adverse event" and 1 indicating "adverse event." 
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Symptom cross-mappings for each product 
z 1 .d t rt t (Amb. ) o1p1 em a ra e 1en 
MedWatcher Social MedDRA Terms 
Sym]!_tom Concept 
altered state of Confusional State; Delirium; Abnormal Behavior; Abnormal 
consciousness Behaviour 
insomnia Insomnia 
ineffective Drug Ineffective 
unidentified Unknown 
sleepiness/tiredness Somnolence; Fatigue 
forgetfulness Amnesia; Memory Impairment 
unusual dreams Abnormal Dreams 
hallucination Hallucination; Hallucination, Visual 
fogginess Disorientation; Depressed Level Of Consciousness 
overdose Overdose; Intentional Overdose 
dizziness Dizziness 
pain Pain 
tolerance Drug Effect Decreased 
feeling bad/ sick Feeling Abnormal 
drug abuse Drug Abuse; Intentional Drug Misuse; Drug Abuser 
hunger I craving Increased Appetite 
addiction Drug Dependence 
headache Headache 
fainting Loss Of Consciousness 
emotional instability Agitation; Aggression 
sleepwalking Somnambulism; Sleep-related Eating Disorder; Sleep 
Walking; Abnormal Sleep-related Event 
anxiety Anxiety 
depression Depression 
fall Fall 
stomach pain Abdominal Pain 
weakness Asthenia 
injury Injury 
lethargy Lethargy 
nonspecific reaction Toxicity To Various Agents; Drug Hypersensitivity; Drug 
Interaction 
impaired vision Visual Impairment 
injection site pain Injection Site Pain 
vomiting Vomiting 
withdrawal Drug Withdrawal Syndrome 
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weight gain Weight Increased 
suicidal thoughts Completed Suicide; Suicidal Ideation 
trouble breathing Respiratory Arrest 
nausea Nausea 
twitching Tremor 
seizure Convulsion 
c r b erto 1zuma pego 1 cc· · ) Imzia 
MedWatcher Social MedDRA Terms 
Symptom Concept 
sleepiness/tiredness Fatigue 
abdominal pain Abdominal Pain; Abdominal Pain Upper 
Crohn's Crohn's Disease 
diarrhea Diarrhoea; Frequent Bowel Movements 
ineffective Drug Ineffective 
joint pain Arthralgia 
nausea Nausea 
fever Pyrexia 
rash Rash 
pam Pain; Pain In Extremity 
feeling bad/ sick Malaise; Feeling Abnormal 
vomiting Vomiting 
headache Headache 
got worse Condition Aggravated 
injection site pain Injection Site Pain; Injection Site Reaction 
pneumonia Pneumonia 
smus Nasopharyngitis; Sinusitis; Upper Respiratory Tract Infection 
trouble breathing Dyspnoea 
weakness Asthenia 
weight loss Weight Decreased 
dizziness Dizziness 
UTI Urinary Tract Infection 
swelling Oedema Peripheral 
cough Cough 
psoriasis Psoriasis 
itching Pruritus 
infection Infection 
bloating Abdominal Distension 
dehydration Dehydration 
back pain Back Pain 
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flu-like illness Influenza Like Illness 
muscle spasms Muscle Spasms 
rash Urticaria 
pregnancy Pregnancy 
bronchitis Bronchitis 
shingles Herpes Zoster 
constipation Constipation 
anemia Haemoglobin Decreased 
decreased appetite Decreased Appetite 
insomnia Insomnia 
sore throat Oropharyngeal Pain 
tingling Paraesthesia 
n· th 1 fu 1me tyJ t (T fid ) mara e ec era 
MedWatcher Social MedDRA Terms 
Symptom Concept 
hot flashes Flushing; Hot Flush 
nausea Nausea 
diarrhea Diarrhoea 
vomiting Vomiting 
abdominal pain Abdominal Pain Upper; Abdominal Discomfort; 
Abdominal Pain; Gastric Disorder; Gastrointestinal 
Disorder 
itching Pruritus 
sleepiness/tiredness Fatigue 
rash Rash; Urticaria 
headache Headache 
red skin Erythema 
pain Burning Sensation; Pain; Pain In Extremity 
dizziness Dizziness 
weakness Asthenia; Muscular Weakness 
fever Pyrexia 
bloating Abdominal Distension 
feeling hot Feeling Hot 
muscle spasm Muscle Spasms 
constipation Constipation 
tingling Paraesthesia 
got worse Multiple Sclerosis Relapse 
stumble Gait Disturbance 
dehydration Dehydration 
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decreased appetite Decreased Appetite 
feeling bad/ sick Malaise; Feeling Abnormal 
numbness Hypo aesthesia 
trouble breathing Dyspnoea 
farting Flatulence 
weight loss Weight Decreased 
chills Chills 
insomnia Insomnia 
sweating Hyperhidrosis 
UTI Urinary Tract Infection 
back pain Back Pain 
forgetfulness Memory Impairment 
fall Fall 
nonspecific reaction Hypersensitivity 
flu-like illness Influenza Like Illness 
joint pain Arthralgia 
hair loss Alopecia 
heartburn Dyspepsia 
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